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Abstract
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder that affects over 6
million people worldwide. Despite being the most common movement disorder in the U.S., there is still no
effective treatment for halting the progression of disease. While generally considered a sporadic and idiopathic
disorder, a number of mutations in genetic loci causal for PD have provided valuable insight into the etiology
of disease. Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are the single most common cause
of both familial and sporadic forms of PD. LRRK2 is a large 2527‐amino acid protein with several distinct
domains: leucine-rich repeats, Ras-like GTPase domain, C-terminal of ROC (COR) domain, serine/
threonine kinase domain, and WD40 repeats; however the understanding of LRRK2 function or how its
aberration may lead to disease is still rudimentary. In 2006, we identified and characterized 3 patients with the
G2019S LRRK2 mutation; however this search was limited to a few sequenced exons. An expanded screen
identified 2 new patients with LRRK2 mutation, and the clinical and neuropathological findings for all these
patients are provided herein. A novel system to express and purify the full-length protein with active in-vitro
kinase activity revealed that the most common disease causing alteration (G2019S) markedly increases kinase
activity. This highlighted overactive kinase activity as a possible intervention point for its aberrant effects.
Screening for molecular inhibitors of kinase activity identified several compounds (Gö6976, K252a, and
staurosporine) that share a basic indolocarbazole structure, which act as potent inhibitors of LRRK2 at low
nanomolar concentrations. Increased kinase activity in the absence of outside factors is unlikely to account for
the pathogenicity of the G2019S mutation. A more careful analysis of LRRK2 kinase activity revealed that this
mutation, relative to the wildtype and other pathogenic mutations, may act in a novel pathway leading to
disease by disrupting LRRK2 sensitivity to manganese kinase inhibition. Furthermore, based on kinetic data,
we propose a novel hypothesis that LRRK2 may act as a cellular sensor of manganese levels, and disruption of
this function may contribute to disease.
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ABSTRACT 
 
THE PATHOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF 
LEUCINE-RICH REPEAT KINASE 2 IN PARKINSON’S DISEASE 
Jason P. Covy 
Advisor: 
Benoit I. Giasson Ph.D. 
 
Parkinson’s disease (PD) is a debilitating and progressive neurodegenerative disorder that 
affects over 6 million people worldwide.  Despite being the most common movement 
disorder in the U.S., there is still no effective treatment for halting the progression of 
disease. While generally considered a sporadic and idiopathic disorder, a number of 
mutations in genetic loci causal for PD have provided valuable insight into the etiology of 
disease.  Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are the single 
most common cause of both familial and sporadic forms of PD.  LRRK2 is a large 
2527‐amino acid protein with several distinct domains: leucine-rich repeats, Ras-like 
GTPase domain, C-terminal of ROC (COR) domain, serine/threonine kinase domain, and 
WD40 repeats; however the understanding of LRRK2 function or how its aberration may 
lead to disease is still rudimentary.   
In 2006, we identified and characterized 3 patients with the G2019S LRRK2 mutation; 
however this search was limited to a few sequenced exons. An expanded screen identified 
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2 new patients with LRRK2 mutation, and the clinical and neuropathological findings for 
all these patients are provided herein.  A novel system to express and purify the full-
length protein with active in-vitro kinase activity revealed that the most common disease 
causing alteration (G2019S) markedly increases kinase activity.  This highlighted 
overactive kinase activity as a possible intervention point for its aberrant effects.  
Screening for molecular inhibitors of kinase activity identified several compounds 
(Gö6976, K252a, and staurosporine) that share a basic indolocarbazole structure, which 
act as potent inhibitors of LRRK2 at low nanomolar concentrations. 
Increased kinase activity in the absence of outside factors is unlikely to account for the 
pathogenicity of the G2019S mutation.  A more careful analysis of LRRK2 kinase 
activity revealed that this mutation, relative to the wildtype and other pathogenic 
mutations, may act in a novel pathway leading to disease by disrupting LRRK2 
sensitivity to manganese kinase inhibition. Furthermore, based on kinetic data, we 
propose a novel hypothesis that LRRK2 may act as a cellular sensor of manganese levels, 
and disruption of this function may contribute to disease. 
  
vii 
 
Table of Contents 
DEDICATION .....................................................................................................................ii 
ACKNOWLEDGMENTS .................................................................................................. iii 
ABSTRACT ......................................................................................................................... v 
LIST OF FIGURES AND TABLES.................................................................................... x 
 
CHAPTER ONE  GENERAL INTRODUCTION ............................................................. 1 
1. Parkinson’s Disease ................................................................................................. 2 
1.1 Pharmacology and Anatomy of the Nigrostriatal System Relevant to PD ....... 3 
2. Pathogenesis of PD .................................................................................................. 5 
2.1 Mitochondrial Damage ..................................................................................... 5 
2.2 Environmental Risks and Toxins ...................................................................... 7 
2.3 Oxidative Stress ................................................................................................ 8 
2.4  Ubiquitin Proteasome System .......................................................................... 8 
2.5  Alpha-Synuclein: The First Link to Protein Dysfunction and Disease ............ 9 
2.6  The Tau protein in PD .................................................................................... 10 
3. Genetic findings in Parkinson’s disease ................................................................ 11 
3.1  PARK1/4 : Alpha-synuclein ........................................................................... 13 
3.2  PARK2: Parkin ............................................................................................... 14 
3.3  PARK6: Pink1 ................................................................................................ 15 
3.4 PARK9: ATP13A2 ......................................................................................... 16 
3.5  PARK8: Leucine-Rich Repeat Kinase 2, Dardarin ........................................ 16 
4. The Role of LRRK2 ............................................................................................... 18 
4.1  Expression and Localization ........................................................................... 18 
4.2  Kinase Domain Activity ................................................................................. 20 
4.3  ROC Activity: GTP Binding and GTPase Activity ........................................ 23 
4.4  Non-Enzymatic LRRK2 Domains .................................................................. 27 
5. Mutations in LRRK2 and its Link to PD ............................................................... 30 
5.1  The Pathology of Cases with LRRK2 Mutation ............................................. 30 
5.2  LRRK2 Kinase Domain Mutations are the Most Prominent Cause of PD .... 35 
viii 
 
5.3  The Common G2019S Pathological Mutation Increases Kinase Activity ..... 35 
5.4  LRRK2 Kinase Activity is Linked to Neurotoxicity ...................................... 36 
5.5  Mutations Outside of the Kinase Domain can Affect Kinase Activity .......... 41 
6. Scope of this Research ............................................................................................... 43 
 
CHAPTER TWO  CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF 
PATIENTS WITH LEUCINE-RICH REPEAT KINASE-2 MUTATIONS .................... 45 
ABSTRACT .................................................................................................................. 46 
INTRODUCTION ......................................................................................................... 47 
MATERIALS AND METHODS .................................................................................. 49 
Antibodies .................................................................................................................. 49 
Molecular Genetic Analysis of LRRK2 ..................................................................... 50 
Immunohistochemistry and Immunofluorescence ..................................................... 51 
RESULTS ...................................................................................................................... 52 
Genetic Analysis of LRRK2: ..................................................................................... 52 
Clinical and Pathological Findings in Cases Harboring the R793M and L1165P 
Mutations in LRRK2: ................................................................................................. 53 
Phosphorylation of S129 in α-Synuclein in the Pathological Inclusions of Patients 
with LRRK2 Mutations .............................................................................................. 55 
TDP-43 Cytoplasmic Inclusions in Patients with LRRK2 Mutations........................ 56 
DISCUSSION ................................................................................................................ 57 
 
CHAPTER THREE  IDENTIFICATION OF COMPOUNDS THAT INHIBIT THE 
KINASE ACTIVITY OF LEUCINE-RICH REPEAT KINASE 2 .................................. 62 
ABSTRACT .................................................................................................................. 63 
INTRODUCTION ......................................................................................................... 64 
MATERIALS AND METHODS .................................................................................. 65 
Materials ..................................................................................................................... 65 
Cell Culture ................................................................................................................ 66 
LRRK2 Expression Constructs .................................................................................. 66 
Western Blotting Analysis ......................................................................................... 67 
ix 
 
In-Vitro LRRK2 Kinase assays .................................................................................. 67 
RESULTS AND DISCUSSION .................................................................................... 69 
Generation and Characterization of Active Full-Length GST-LRRK2. .................... 69 
Recombinant GST-LRRK2 was used to Screen a Range of Defined Kinase Inhibitors.
 .................................................................................................................................... 72 
 
CHATPER FOUR  THE PATHOGENIC G2019S MUTATION DISRUPTS 
SENSITIVITY OF LEUCINE-RICH REPEAT KINASE 2 TO MANGANESE KINASE 
INHIBITION ..................................................................................................................... 75 
ABSTRACT .................................................................................................................. 76 
INTRODUCTION ......................................................................................................... 77 
MATERIALS AND METHODS .................................................................................. 79 
Materials ..................................................................................................................... 80 
Cell Culture ................................................................................................................ 80 
LRRK2 Expression Constructs .................................................................................. 80 
Western Blotting Analysis ......................................................................................... 81 
In-Vitro LRRK2 Kinase Assays ................................................................................. 82 
RESULTS ...................................................................................................................... 83 
DISCUSSION ................................................................................................................ 97 
 
CHAPTER FIVE  SUMMARY AND FUTURE DIRECTIONS ................................... 103 
Patients With LRRK2 Mutations Present with Classical and Nonclassical Pathology, 
Regardless of Mutation Location ................................................................................ 104 
LRRK2 is an Active Kinase that can be Targeted for Possible Therapeutic Intervention
 ..................................................................................................................................... 106 
The G2019S Mutation May Alter LRRK2 Function, in Addition to Overall Activity 108 
Future Directions for Studying LRRK2 in PD ............................................................ 111 
BIBLIOGRAPHY ........................................................................................................... 115 
 
  
x 
 
LIST OF FIGURES AND TABLES 
Chapter One 
Figure 1-1. Neurochemical pathways of the basal ganglia involved in PD.   
Table  1-1. Genetic loci implicated in Parkinson’s disease.   
Figure 1-2. Human ROCO proteins.   
Figure 1-3. Biochemical characterization of LRRK2 protein in human and mouse tissue.  
Figure 1-4. Histological characterization of patients with LRRK2 mutations.  
Figure 1-5. Characterization of LRRK2 antibodies.  
Figure 1-6.  LRRK2 aggregates in transfected COS-7 cells.   
Chatper Two 
Figure 2-1. Identification of patients with LRRK2 mutations and sequence alignment of 
amino acids surrounding the mutations.  
Figure 2-2. Histological characterization of patients with LRRK2 mutations.  
Figure 2-3. Double-labeling immunofluorescence analysis of α-synuclein phosphorylated 
at S129 in pathological inclusions of patients with LRRK2 mutations 
Figure 2-4. TDP-43 cytoplasmic inclusions in patients with LRRK2 mutations  
Chapter Three 
Figure 3-1. Characterization of recombinant GST-LRRK2 activity.  
Figure 3-2. Analysis of GST-LRRK2 kinase activity in the presence of various inhibitors.  
Chapter Four 
Figure 4-1. Characterization of recombinant LRRK2 kinase activity 
Figure 4-2. Analysis of wildtype and G2019S LRRK2 kinase activity in the presence of 
various inhibitors.  
Figure 4-3. Substrate specificity of wildtype and G2019S LRRK2.  
Figure 4-4. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of 
wildtype, R1441C, G2019S, and I2020T LRRK2 on LRRKtide phosphorylation. 
xi 
 
Figure 4-5. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of 
wildtype, R1441C, G2019S, and I2020T LRRK2 on Nictide phosphorylation. 
Figure 4-6. Concentration dependent affects of Mg2+ and Mn2+ on the 
autophosphorylation activity of wildtype and G2019S LRRK2. 
Figure 4-7.  Kinetic characteristics of wildtype and LRRK2 mutations while varying the 
concentration of LRRKtide as a substrate.  
Figure 4-8.  Kinetic characteristics of wildtype and LRRK2 mutations while varying the 
concentration of ATP as a substrate.  
Figure 4-9. Analysis of effects of sub-stoichiometric concentrations of Mn2+ on wildtype 
and mutant LRRK2 kinase activity driven by Mg2+. 
 
1 
 
 
 
 
 
 
CHAPTER ONE 
 
GENERAL INTRODUCTION  
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1. Parkinson’s Disease 
Parkinson’s disease (PD) is the most prevalent movement disorder in the United States 
(190).  It affects over 6 million people worldwide, and is the second most common 
neurodegenerative disorder after Alzheimer’s disease (104, 292).  PD primarily affects 
those over the age of 55, and the incidence of disease sharply rises after the age of 65 
with as many as 50,000 new cases identified each year in the United States (236).   
The disease was first described in 1817 by James Parkinson in a paper entitled “An Essay 
on the Shaking Palsy”, and his clinical observations still serve as the basis for disease 
classification.  PD presents as a broad clinical spectrum with the cardinal symptoms of 
trembling at rest, rigidity, bradykinesia (slowness of movement), postural instability, and 
a therapeutic responsiveness to L-dopa, the precursor of dopamine (292). A definite 
diagnosis can only be confirmed by pathological post-mortem analysis (104), as a 
number of other closely related neurological disorders (termed Parkinsonisms) present 
with similar PD-like symptoms.  Pathologically, PD is characterized by a loss of 
(primarily dopaminergic) neurons in the substantia nigra pars compacta (SNpc) with 
alpha-synuclein positive proteiniacous inclusions, known as Lewy bodies (LBs) and 
Lewy neurites (LNs), present in some of the surviving neurons (58, 92, 93).  During the 
normal aging process, approximately 0.1-0.2% of the 400,000 dopaminergic neurons in 
this area are lost per year, however, in the case of patients with PD, this rate is greatly 
accelerated (40, 327).  Symptoms of the disease manifest when ~70-80% of these 
neurons have been lost (63, 252).  Currently, the causes and mechanisms of the selective 
and accelerated loss of cells in the SN remain unclear, and no cure for PD exists. 
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1.1 Pharmacology and Anatomy of the Nigrostriatal System Relevant to PD 
The progressive degeneration within the substantia nigra (SN) and subsequent loss of 
dopaminergic output to the striatum is the major factor contributing to the disruption of 
motor control in PD.  The SN, caudate nucleus, putamen, globus pallidus (GP), and 
subthalamic nucleus (STN) are the five major nuclei of the basal ganglia, which, 
alongside the thalamus, receive and process input and provide feedback to the cerebral 
cortex for the generation and initiation of voluntary movement.   
The principal circuit associated with the basal ganglia is a loop projecting from the 
cerebral cortex to the basal ganglia, to the thalamus, and back to the cortex (Figure 1-1). 
These connections may be accomplished through two overlapping but distinct circuits: 
the direct and indirect pathways.  These pathways have competing effects on movement, 
and the balance between them is involved in establishing and regulating tone.  The direct 
pathway facilitates movement and projects from the cortex to the striatum (the caudate 
nucleus and the putamen), then to the internal segment of the GP (GPi), before 
proceeding to the thalamus, and back to the cortex.  The indirect pathway inhibits 
movement and also projects from the cortex, but goes to the external segment of the GP 
(GPe) followed by the STN before connecting to the GPi to complete the loop to the 
thalamus and cortex.  Axons leaving the striatum and GP use γ-aminobutyric acid 
(GABA) as a neurotransmitter to make inhibitory synapses.  Pallidal neurons are 
tonically active, therefore inhibiting parts of the thalamus. 
The SN projects to all areas of the striatum in a point-to-point fashion by way of very fine 
axons, and cells within the ventrolateral tier of SN pars compacta (SNpc), which project 
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to the dorsal putamen, are those predominately involved in motor coordination. This area 
of the SNpc degenerates earlier and to a greater extent than other regions within the SN, 
and destruction of this nigrostriatal pathway is the major factor causing the disruption of 
motor control in PD.  The SN pars reticulata (SNr) utilizes GABA while the SNpc uses 
dopamine as its neurotransmitters. The SNpc projects to the striatum, exciting some 
striatal neurons through D1 and D5 receptors, and inhibiting others through D2-D4 
receptors.  The striatum and STN both project to the SNr, which projects inhibitory 
synapses to the thalamus.  Loss of dopamine input to the basal ganglia from the SNpc 
causes increased inhibition of the ventral anterior nucleus of the thalamus, which sends 
excitatory glutamatergic projections to the motor cortex, leading to hypokinesia.  
Supplementing the loss of dopamine with the dopamine precursor L-dopa remains the 
mainstay for therapy. 
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Figure 1-1. Neurochemical pathways of the basal ganglia involved in PD.  (Left) The neuroanatomy of 
the basal ganglia.  Areas of degeneration are colored in yellow. (Right) The neurocircuitry of the basal 
ganglia’s direct and indirect pathways are both represented.  Excitatory synapses are denoted by black 
arrows, while inhibitory synapses are denoted by red arrows.    Figure adapted from Lozano et al (190). 
2. Pathogenesis of PD 
PD is primarily considered a sporadic and idiopathic disorder.  An early study examining 
the concordance rates of PD in 19,842 monozygotic and dizygotic male twins bolstered 
this point of view when genetic factors played were found to play no major role in 
causing typical PD (313).  Generally, PD was believed to be caused by environmental 
factors or toxins; a view that was greatly strengthened in 1982 through the discovery of a 
small number of PD cases reported in a younger cohort of patients (191).  Upon close 
investigation of these patients, it was found that they all had contracted PD through use of 
a tainted source of synthetic heroin.  A faulty step in the purification process led to the 
byproduct 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which was found to be 
a selective neurotoxin for dopaminergic neurons.  
2.1 Mitochondrial Damage 
6 
 
MPTP is metabolically converted by glia into the active metabolite MPP(+) (246, 272).  
Attributed to its structural similarity to dopamine, MPP(+) is a selective substrate for the 
dopaminergic transporter, and upon uptake by dopaminergic neurons, it can inhibit 
complex I of the electron transport change, resulting in a modest decline of ATP and the 
generation of reactive oxygen species (ROS) (80, 189, 301).  As neurons are highly 
metabolically active, mitochondrial impairment can be devastating to their function.  
Furthermore, the mitochondria is a key area for regulation of apoptosis and cell survival 
(188, 247).   
Rotenone, an insecticide that also inhibitrs complex 1, has been shown to cause selective 
loss of dopaminergic neurons in the SNpc, alpha-synuclein positive fibrillar inclusions, 
and behavioral changes consistent to PD upon chronic intravenous administration in rats 
(although, in this model, the depletion of striatal neurons and development of tau-positive 
inclusions in cortical neurons have also been reported, inconsistent with PD) (22).  
However, a more recent mouse model with a disruption in the gene for mitochondrial 
transcription factor A (Tfam) in dopaminergic neurons more closely resembles the 
etiological progression of PD (100).  This conditional knockout has reduced 
mitochondrial DNA expression and respiratory chain function in midbrain dopaminergic 
neurons, intraneuronal inclusions and dopamine cell death, and adult onset impairment of 
movement. 
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2.2 Environmental Risks and Toxins 
The greatest risk factor for PD is age (226, 238, 330).  As previously stated, nigrostriatal 
loss of neurons is about 0.1-0.2% per year, however this number increases with age (40).  
Outside of this common risk factor, there are a number of other not-so-common factors 
that confer increased risk of Parkinsonism and PD.  These range from rare insecticides 
like paraquat, to more ubiquitous metals such as manganese (16, 181, 312). 
The pesticide paraquat has some structural similarity to MPTP, and has been shown in 
rats to cross the blood brain barrier and to lead to nigral dopaminergic cell demise (37).  
The metabolism of paraquat leads to the production of reactive semiquinones and ROS, 
which can induce oxidative stress and damage to the cell (227, 228) (discussed further 
below).  Manganese is an essential trace mineral necessary for normal development and 
biological function (277).  It is mainly taken in through the diet, and toxic levels are 
usually not reached unless individuals experience dramatic reductions in excretion due to 
liver failure (177); however, overexposure has been found in miners and welders (59, 
268).  Manganese causes preferential damage to the gloubus pallidus, which may be due 
in part to the ability of manganese to activate this area’s glutamatergic machinery, which 
may potentiate overall manganese cytotoxicity (14, 335). Manganese can initiate 
apoptosis by disrupting the mitochondria, where it is rapidly taken up within the cell 
(103).  Here, it can promote disruption of complex I, calcium accumulation and 
subsequent activation of the permeability transition pore, and activation of caspase 3 
(278).  Furthermore, manganese may provide a more selective threat to dopaminergic 
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neurons as the dopamine transporter may also be involved in the accumulation of 
manganese (8, 85). 
2.3 Oxidative Stress 
Post-mortem analysis of PD brains show increased lipid peroxidation, oxidative 
modifications to proteins and DNA, depletion in levels of antioxidants such as 
glutathione, and high levels of iron (71, 289); all markers of oxidative stress.  
Dopaminergic neurons may already be subject to higher levels of oxidative stress from 
the auto-oxidation and catabolism of dopamine, which produces electrophilic 
semiquinones and quinones (90, 162). Monoamine oxidase, which is involved in the 
breakdown of dopamine and other bicyclic amines, produces H202 as a normal by-product 
of its metabolic process.  Additionally, the auto-oxidation of dopamine into melanin can 
produce reactive oxygen species (20, 128). 
2.4  Ubiquitin Proteasome System 
Protein deposits are common to many neurodegenerative disorders, and are usually the 
result of decreased solubility, improper protein folding, and/or dysfunction in protein 
clearance by the ubiquitin proteasome system (UPS) (237).  The main function of the 
UPS is to identify, ubiquitinate, and proteolytically degrade intracellular proteins (44, 
333).  Failure to do so causes protein accumulation which may lead to toxicity and 
ultimately cell death (126).  Within the context of PD, the proteinacious inclusions 
known as LBs are rife with polyubiquitinated proteins, suggesting an inability of the 
proteasome to degrade these proteins (319).  Within the SN of PD patients, reports have 
shown that enzymatic activity at the level of the proteasome is impaired compared to 
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controls, as well as other brain regions, and there appears to be a selective loss of 26/20S 
proteasome alpha-subunits (229, 230).  ATP is required for the proper assembly and 
function of the 26S proteasome complex (144), and both the 26S and 20S are selectively 
vulnerable to oxidative stress (38).  Altogether, mitochondrial deficits in complex I and 
the generation of ROS both present problems for the UPS, making this a key area 
affected in PD. 
2.5  Alpha-Synuclein: The First Link to Protein Dysfunction and Disease 
A number of protein candidates have been associated with PD, however the most well 
known and prominent is the synuclein protein.  Synuclein was originally identified in 
1998 from Torpedo californica (221), and its name was derived at the time from its 
apparent localization to the nuclear envelope of neurons as well as presynaptic nerve 
terminals.  There are three members of the synuclein family of proteins: alpha-, beta-, and 
gamma-synuclein. They range in weight from 14-20 kDa, however the alpha and beta are 
more closely related than the gamma-synuclein (46).  
Alpha-synuclein is a 140 amino acid protein with three distinct regions: an amphiphatic 
N-terminal region, a central hydrophobic region, and a highly acidic and proline-rich 
region.  The protein is natively unfolded and assumes a random-coil formation in the 
cytosol, but will adopt a secondary structure upon binding to the membrane, or during the 
process of aggregation (64, 83, 341).  Shortly after PD associated mutations were 
identified in alpha-synuclein (discussed below), an antibody developed against the 
protein showed positive staining in LBs and LNs.(298, 299)  It soon became clear that 
alpha-synuclein was the main component of these pathological hallmarks, and the 
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polymerization of soluble alpha-synuclein into amyloid fibrils form the main structures of 
these cellular inclusions (161, 325). 
In an environment of oxidative stress, alpha-synuclein can undergo several post-
translational modifications that influence aggregation: tyrosine nitration, methionine 
oxidation, and dopamine adduct formation (106, 184, 348).  Oxidative cross-linking at 
tyrosine residues can form alpha-synuclein dimers, which could be toxic in cellular 
models (151, 185, 352).  Little is known of the actual role alpha-synuclein plays within 
the central nervous system, although it has been implicated in the function of the Golgi 
apparatus, vesicle trafficking, and SNARE complexes as a molecular chaperone (2, 49, 
317).  Deletion of alpha-synuclein in mice does not lead to disease, thereby suggesting a 
toxic gain of function for the protein itself, however even more controversial is the extent 
that the alpha-synuclein proteinacious inclusions may play in PD; whether it is an active 
toxin, a saving sponge, or just a passive artifact of another pathological pathway.  
Regardless of the role, alpha-synuclein has a major presence in the pathology and 
possibly pathogenesis of disease. 
2.6  The Tau protein in PD 
Tau is another dominant protein found in protein aggregates that are associated with 
neurodegenerative disorders (196).  Tau is part of the microtubule-associated protein 
(MAP) family whose main function is to modulate the stability of microtubules.  In 
neuronal cells, tau expression is highest in the axons of neurons, however low levels can 
also be detected in oligodendrocytes and astrocytes.  Tau acts to assemble and stabilize 
tubulin monomers into microtubules, and is important in axonal extension, transport of 
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vesicles and organelles along microtubules, and morphogenesis (51, 281).   Like 
synuclein, tau can aggregate to form intracellular and extracellular protein inclusions, and 
is a pathological hallmark in a variety of disorders including Alzheimer’s disease, 
frontotemporal dementia, and Pick’s disease.  In regards to PD, tau pathology has been 
found in some LBs of cases with idiopathic PD (11), as well as other Parkinsonisms such 
as progressive supranuclear palsy and corticobasal degeneration (300).  In vitro, alpha-
synuclein and tau synergistically act to promote the fibrillization of each other (107), and 
alpha-synuclein can bind to tau to stimulate tau phosphorylation by protein kinase A 
(163).  In vivo, mice expressing the aggregate enhancing A30P mutation of alpha-
synuclein accumulate hyperphosphorylated tau suggestive of an early or pre-aggregated 
form, concomitant with alpha-synuclein aggregation (94).  Together, these findings 
suggest that alpha-synuclein may interact with tau to cause pathological changes in 
disease. 
3. Genetic findings in Parkinson’s disease 
 
The discovery of various gene defects associated with PD has revolutionized the 
mechanisms of disease pathogenesis.  Since the previously mentioned twin study, a 
number of specific genetic candidates have shed light on potential molecular pathways 
leading to degeneration and malfunction of the nigrostriatal pathway.  Linkage studies 
have implicated components of protein overexpression leading to aggregation, alongside 
dysfunction of the ubiquitin proteasome pathway exacerbating issues of protein 
misfolding and accumulation, in addition to genes involved in oxidative stress, post-
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translational modification, and metal homeostasis.  5-10% of patients with PD are known 
to have a monogenic form of the disease, and at least 15 genetic loci have been linked to 
PD, of which 10 have been mapped to a specific gene (Table 1-1) (197, 344).  
Locus 
(gene) 
Map 
Position 
Protein Putative function Inheritance pattern 
PARK1/ 
PARK4 
SNCA 
4q21 alpha-synuclein Presynaptic protein, 
neurotransmission, vesicle 
recycling 
AD/EOPD with rapid 
progression and 
dementia, sporadic 
PARK2  
PARKIN 
6q25–
q27 
parkin Ubiquitin E3 ligase, has 
neuroprotective function 
AR/juvenile and EOPD 
with slow progression, 
dystonia; sporadic 
PARK3? 2p13 sepiapterin reductase Involved in biosynthesis of 
tetrahydrobiopterin (BH4) 
AD/LOPD, dementia 
PARK5 
UCH-L1 
4p14 ubiquitin carboxyl-terminal 
hydrolase isozyme L1 (UCH-
L1) 
Ubiquitin hydrolase AD/LOPD 
PARK6 
PINK1 
1p35–
p36 
PTEN-induced putative 
kinase 1 (PINK1) 
Mitochondrial S/T-protein kinase, 
has neuroprotective function 
AR/EOPD with slow 
progression, tremor 
PARK7 
DJ-1 
1p36 DJ-1 Chaperone, antioxidant, 
neuroprotective, RNA binding 
AR/EOPD, dystonia, 
psychiatric symptoms 
PARK8 
LRRK2 
12q12 Leucine-rich repeat kinase 2 
(LRR2) 
Protein kinase, protect cells from 
stress-induced mitochondrial 
dysfunction 
AD/LOPD, tremor 
PARK9 
ATP13A
2 
1p36 ATP13A2/probable cation-
transporting ATPase 13A2 
Lysosomal ATPase 
Probable cation-transporting 
AR/juvenile Kufor-
Rakeb syndrome, 
EOPD 
PARK10
? 
1p32 UPS24/ubiquitin carboxyl-
terminal hydrolase 24 
Involved in the ubiquitin-
dependent proteolytic pathway 
Unclear/LOPD 
PARK11
? 
2q36–
q37 
GIGYF2/PERQ amino acid-
rich with GYF domain-
containing protein 2 
Involved in regulation of tyrosine 
kinase receptor signaling 
AD/LOPD 
PARK12 Xq12–
q25 
Unknown Unknown Unclear 
PARK13 2p13 HTRA2/serine protease 
HTRA2, mitochondrial 
Serine protease, may be involved 
in mitochondrial dysfunction 
Unclear 
PARK14
? 
22q13.1 PLA2G6/85 kDa calcium-
independent phospholipase 
A2 
Catalyzes the release of fatty 
acids from phospholipids 
AR/juvenile,levodopa-
responsive dystonia 
parkinsonism 
PARK15
? 
22q12–
q13 
FBXO7/F-box only protein 7 Involved in the ubiquitin-
dependent proteolytic pathway 
AR/EO, parkinsonian-
pyramidal syndrome 
Not 
assigned 
2q22–
q23 
NR4A2/nuclear receptor 
subfamily 4 group A member 
2 
Probable nuclear receptor. May 
function as a general coactivator 
of gene transcription 
AD? 
Not 
assigned 
5q23.1–
q23.3 
SNCAIP/synphilin-1 Interact with alpha-synuclein, 
substrate of parkin, part of LBs 
Unknown 
Not 
assigned 
15q25 POLG/DNA polymerase 
subunit gamma-1 
Mitochondrial DNA polymerase 
catalytic subunit 
AD, AR/EOPD 
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Table 1-1. Genetic Loci implicated in Parkinson’s disease.  Known and unknown genetic loci are listed 
alongside their chromosomal mapping, gene and protein product, putative protein function, and model of 
genetic inheritance.  Question marks indicate candidates still under investigation. AD, autosomal-dominant; 
AR, autosomal-recessive; EO, early onset; LO, late onset; PD, Parkinson’s disease; PM, point mutations; 
HM, heterozygous mutations.  Table adapted from Shadini et al 2010 (285). 
3.1  PARK1/4 : Alpha-synuclein 
SNCA (PARK1:alpha-synuclein) was the first gene identified to have a causal role in PD 
(264).  In 1990, Golbe et al reported a large family with an autosomal dominant form of 
parkinsonism: greater than 60 family members over the course of five generations with a 
diagnoses ranging from diffuse LB disease to typical PD (120).  In 1996, Polymeropoulos 
and colleagues identified linkage to the long arm of chromosome 4 (262), and the next 
year a 209g>a (A53T) mutation was identified in alpha-synuclein for this kindred 
alongside three unrelated Greek families (264).  Soon after, two additional synuclein 
mutations were found:  an A30P mutation in a German family (186), and an E46K 
mutation in a Spanish family (351).   
In vitro, alpha-synuclein can form fibrils similar to those seen in LBs (47, 345).  Fibril 
formation is characterized by a slow lag phase that is nucleation dependent, followed by a 
faster elongation phase (345).  The A53T and the E46K mutations have both been shown 
to increase the rate of polymerization; however, the effects of the A30P mutation on fibril 
formation in vitro are not consistent between studies (47, 109, 129).  Regardless, these 
findings implicate a link between alpha-synuclein aggregation and disease.  This theory 
was strengthened by the discovery that the PARK4 loci also mapped to alpha-synuclein 
through its triplication in an Iowa kindred and a Swedish-American family with early-
onset Parkinsonism (87, 294), as well as duplication in three French and Italian families 
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with typical disease onset (41).  The dominant mode of inheritance from expansion of the 
synuclein gene, paired with the greater severity and earlier onset for the triplication 
versus the duplication, suggested a possible “SNCA gene dosage effect” leading to PD 
(293).  This theory is further bolstered by in vitro data which shows that the rate of 
synuclein aggregation is concentration dependent (345).  Consequently, this may explain 
the pathogenicity behind the A30P mutation, as it has been proposed that this mutation’s 
decreased ability to bind lipids may increase its intracellular pool, thereby facilitating 
greater opportunities to aggregate (164). 
3.2  PARK2: Parkin 
The role of reduced protein degradation in PD was further emphasized with the 
identification of mutations in genes affecting the ubiquitin proteasomal degradation 
system:  PARK2 (PARKIN:Parkin) and PARK5 (UCH-L1).  Mutations in the PARKIN 
gene were discovered in 1998, and are the most common form of recessive early-onset 
Parkinsonism (225).  Parkin is a 465 amino acid protein which is widely expressed in the 
cell bodies of neurons in the midbrain, basal ganglia, cerebral cortex, and cerebellum, 
where it functions as an E3 ubiquitin ligase (66).  Traditionally, E3 ligases serve to 
conjugate ubiquitin molecules to specific proteins, thus targeting them for degradation by 
the proteasome (recent evidence suggests ubiquitin may also function in other various 
signaling cascades) (146).  In vitro, Parkin has been shown to interact with the E2 
ubiquitin ligase UbcH7 and 8UbcH8 to promote ubquitination, and pathological 
mutations decrease its ability to conjugate ubiquitin (287).  In 2005, Wang et al found 
that more than half of the 22 reported missense/nonsense mutations reduced Parkin 
15 
 
solubility and increased the propensity of the protein to form aggresome-like aggregates, 
suggesting a mechanism leading to its loss of function (336).  In vivo, Parkin knock-out 
mice show impaired mitochondrial function and increased markers of oxidative stress 
linked to dysregulation of multiple proteins related to oxidative phosphorylation and 
oxidative damage (253).  In 2006, several studies linked Parkin to another genetic 
candidate in PD, PARK6 (ARPD; PTEN-induced putative kinase 1, PINK1) (45, 256). 
3.3  PARK6: Pink1 
After DJ-1, PINK1 was the third gene to be associated with autosomal recessive PD 
(328).  Pink1 is a 581 amino acid protein ubiquitously expressed in all brain regions in 
both neurons and glia (at lower levels), and localizes predominately to the mitochondria 
(27, 290).  Structurally, the protein contains a mitochondrial targeting motif and a highly 
conserved serine/threonine kinase-like domain capable of autophosphorylation in vitro 
(326, 328).  Subsequent studies have confirmed Pink1’s ability to undergo in-vitro 
autophosphorylation, and demonstrate that several pathological missense mutations 
decrease kinase activity (18).  While the function of this protein remains unclear, in vitro 
models show that Pink1 overexpression protects against oxidative induced apoptosis 
(259, 328).   In one cellular model, Pink1 protected against oxidative stress by 
phosphorylating TNF receptor-association protein 1 (TRAP1) at the mitochondria (265).  
Pink1 has also been implicated in the phosphorylation and regulation of the 
mitochondrial protease HtrA2 (261).  Through interaction with p38 and HtrA2, Pink1 
may increase HtrA2 protease activity in response to stress.  In vivo, Pink1 knock-out 
mice suffer from elevated susceptibility to oxidative stress, increased mitochondrial 
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calcium levels, loss of mitochondrial membrane potential, reduced synaptic dopamine 
release and plasticity in the striatum, and reduced viability of cortical neuron cultures 
(114, 175).  In Drosophila, Pink1 knockouts develop fragmented mitochondrial cristae, 
hypersensitivity to oxidative stress, and muscle and neuronal degeneration which can be 
rescued by Parkin overexpression; however, Pink1 cannot rescue Parkin deletion, 
indicating that Parkin may function downstream of Pink1 in a disease-relevant pathway 
(45, 256). 
3.4 PARK9: ATP13A2 
ATP13A2 was first associated with Kufor-Rakeb syndrome, a recessive atypical 
Parkinsonism, in 2006 (270).  Splicing and deletion mutations resulting in truncated 
forms of the protein were found in the original family, as well as a family from Chile.  In 
2007, three additional missense mutations were found: G504R, T12M, and G533R (72).  
ATP13A2 is a large 1180 amino acid protein belonging to the lysosomal type 5 P-type 
ATPase family of transporters. Recently, ATP13A2 has been shown to be protective 
against alpha-synuclein induced toxicity in yeast, C. elegans, and rat primary midbrain 
neurons (115).  In addition, ATP13A2 may play a role in sequestering heavy metal ions 
possibly by acting as a lysosomal transporter, as it exhibits protective affects in yeast 
against a number of metals including manganese, cadmium, nickel, and selenium (115, 
283).  Currently, little else is known of this protein’s function. 
3.5  PARK8: Leucine-Rich Repeat Kinase 2, Dardarin 
Of all the genetic loci mapped to PD, the PARK8 locus has generated the most attention 
due to its high prevalence in disease.  In 1997, Hasegawa and Kowa reported a Japanese 
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kindred with an autosomal dominant mode of PD inheritance (139), and five years later 
they were able to determine linkage to the long arm of chromosome 12 (96). In 2004, 
separate studies simultaneously identified the LRRK2 gene in a handful of other families 
responsible for the PARK8 loci (250, 355).  Since then, over 75 sequence variations in 
the gene have been found, and it is regarded as the most common known cause of 
familial and sporadic cases of PD (60). 
The gene for LRRK2 spans ~7.5Mb and contains 51 exons.  It encodes a large 2,527 
amino acid protein with multiple complex domains, including N-terminal leucine-rich 
repeats, a GTPase ROC (Ras of complex proteins) domain followed by COR (C-terminal 
of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) catalytic 
domain, and C-terminal WD40 repeats (Figure 2) (224).  Early studies reported the 
presence of ankyrin domains located in the N-terminal portion of the protein; however, 
later modeling studies do not support their existence (219).  Regardless, there are a 
number of sequences unique to LRRK2 found throughout the N-terminal portion of the 
protein that are conserved across species. 
The characteristic ROC and COR domains of LRRK2 make it a member of the ROCO 
protein family, alongside LRRK1, MFHAS1/MASL1, and DAPK1, which are found in 
humans (Figure 1-2) (219).  At least 40 other ROCO proteins have been identified in 
eukaryotes and prokaryotes, and have been shown to play a role in cytokinesis, cell 
polarity, and chemotaxis (1, 31, 32, 121).  
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Figure 1-2. Human ROCO proteins.  Schematics to scale for each of the ROCO proteins expressed in 
humans with functional domains labeled.  LRR, leucine-rich repeat; ROC, Ras of complex protein; Cor, C-
terminal of ROC; Kin, kinase; WD40, WD40 repeat; D, death domain. 
4. The Role of LRRK2 
Currently, little is known of the biological function of LRRK2.  Multiple studies have 
attempted to elucidate its physiological binding partners, pathological kinase substrates, 
nucleotide binding activity, and signaling pathways; and while a substantial amount of 
information has been reported, a significant number of these findings seem to contradict 
each other.   However, despite these inconsistencies, a general role for LRRK2 is 
beginning to emerge. 
4.1  Expression and Localization 
Expression of LRRK2 has been examined at the mRNA and protein level with some 
minor differences.  LRRK2 is found in numerous tissues including the lungs, heart, liver, 
kidney, spleen, testes, and brain (Figure 1-3) (105, 205, 215).  Within the CNS, LRRK2 
mRNA expression is found in most regions including those affected in PD.  A common 
finding among in-situ hybridization studies utilizing rodent, primate, and human brain, is 
the high levels of mRNA expression in dopaminoreceptive areas directly related to the 
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pathogenesis of PD (101, 232).  Particularly high expression is found in the cerebral 
cortex (pyramidal projection neurons and various interneurons throughout most layers), 
olfactory tubercle, and the striatum (output projection neurons, medium-sized spiny 
neurons) (101, 291).  Medium expression levels have also been identified in the 
cerebellum and hippocampus, and similar results have been obtained at the protein level 
(137, 148, 234). 
 
Figure 1-3. Biochemical characterization of LRRK2 protein in human and mouse tissue. (A) (Left) 
Coomassie-stained gel showing the expression of recombinant His-tagged human LRRK21245-2527 protein 
(~145kDa) as indicated by the arrow. (Right) Western blotting analysis showing that LRRK2 antibody 
AP7099b specifically detects LRRK2 protein and some breakdown products. (B) Immunoblot analysis with 
rabbit anti-LRRK2 antibody AP7099b detecting LRRK2 in postmortem human brain cortex (Hu) 
(~250kDa) and as multiple species between approximately 120 to 130kDa. In various freshly dissected 
mouse tissues (Cx = cortex; Ht = heart; Kd = kidney; Lv = liver; Lg = lung) and in HEK293T cells, 
LRRK2 is predominantly expressed as an ~250kDa protein.  Figure adapted from Giasson et al (105). 
Initial studies had failed to identify LRRK2 mRNA in dopaminergic neurons themselves, 
specifically within the SN (101, 232).  However, late in 2006, a number of new LRRK2 
antibodies allowed for the detection of moderate levels of LRRK2 immunoreactivity 
within the SN (149, 316).  Soon thereafter, Higashi and colleagues utilized mixed 35S-
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labeled oligionucleotides, in lieu of the 33P-labeled methods used previously, and were 
subsequently able to detect low levels of mRNA expression within the SN (148), and this 
finding has since been confirmed in several other studies (137, 291, 316).  Besides 
differences in methodologies, it has been suggested that discrepancies in detecting 
LRRK2 in the SN may result from the instability of LRRK2 mRNA, its short half-life, or 
its transportation to distal sites within nigral dopaminergic pathways (149).  In addition, 
at the protein level, LRRK2 may have a long half-life in this population of neurons thus 
requiring low levels of mRNA. 
4.2  Kinase Domain Activity 
Aberrant protein phosphorylation is a common finding in a variety of neurodegenerative 
disorders.  Alongside Pink1, LRRK2 is one of two kinases implicated in monogenetic 
forms of PD.  Within the family of human ROCO genes, kinase domains can be found in 
LRRK1, LRRK2, and DAPK1.  The DAPK1 kinase domain bears closest resemblance to 
the calcium/calmodulin-dependent kinase (CAMK) family, while both LRRK genes were 
classified within the tyrosine kinase-like (TKL) sub-family, with LRRK2 bearing closest 
homology to the mitogen-activated protein kinase kinase kinase (MAPKKK) family (32, 
219) and the receptor-interacting protein kinase (RIPK) family (130). 
The study of LRRK2 kinase activity has been complicated by the varied complex 
domains and overall size of the protein.  As such, most studies to assess biochemical 
activity have relied on smaller truncated versions, while only a few have successfully 
utilized the full-length protein for qualitative analysis.  The first obstacle in assessing the 
kinase activity of LRRK2 was identifying a substrate.  Luckily, it was found that LRRK2 
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has the ability to autophosphorylate (117, 342).  Sites of autophosphoyrlation within the 
kinase domain have been suggested to take place on residues T1967, T1969, T2031, 
S2032, and T2035 (residues in bold have been confirmed in at least 2 or more studies) 
(116, 134, 167, 203, 213) and can occur in a cis or trans manner (134, 213).  
Autophosphorylation appears to be critical for subsequent kinase activity and proper 
dimerization of LRRK2 (213, 284), and conversely, some kinase inhibitors have the 
ability to disrupt this dimerization (284). 
In addition to autophosphorylation, myelin basic protein (MBP) has proven to be a well 
tolerated generic substrate, illustrating LRRK2’s ability to phosphorylate targets beside 
itself.  To extend the identification of kinase substrates of LRRK2 towards physiological 
targets, Jaleel and colleagues utilized a kinase substrate tracking elucidation (KESTREL) 
screen of brain tissue from rodents.  In doing so, they were able to identify moesin (for 
membrane organizing extension spike protein), a member of the ezrin, radixin, moesin 
(ERM) family of proteins (160). ERM proteins crosslink actin filaments with membranes, 
and contain the following domains: an N-terminal globular FERM domain, and extended 
alpha-helical domain, and a charged C-terminal domain (36).  This protein family has 
been shown to be involved in cell shape, growth, and motility (89).  Since its initial 
discovery as a LRRK2 substrate in 2007, only one study from 2009 has been able to 
show physiological evidence linking the ERM protein family to LRRK2 (255).  Therein, 
primary neurons cultured from G2019S LRRK2 transgenic mice showed increased 
numbers of pERM-positive and F-actin enriched filopodia, which coincided with 
retardation of neurite outgrowth.  Regardless of whether moesin is a physiological 
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substrate, the conserved sequence surrounding the phosphorylation motif in the ERM 
family was synthesized into a peptide and termed LRRKtide (RLGRDKYKTLRQIRQ).  
This peptide is specifically and robustly phosphorylated by LRRK2 in vitro (53, 160), 
and has become the standard substrate for biochemical testing. 
Because LRRK2 bears sequence homology to the MAPKKK family, attempts have been 
made to identify potential substrates within the mitogen-activated protein kinase (MAPK) 
cascade.  The MAPK cascade is a three-tiered signaling pathway beginning with 
extracellular stimulation of MAPKKKs.  Upon stimulation, they will phosphorylate a 
MAP kinase kinase (MAPKK), which will then go on to phosphorylate a MAPK: signal 
transducing enzymes that regulate diverse cellular responses (173, 307).  MKK3/6 and 
MKK4/7 were found to be mildly phosphorylated by LRRK2 in vitro at residues 
necessary for their activation of c-JUN and p38 respectively (118).  This finding was 
subsequently replicated for MKK3, 6, and 7, albeit weakly, but not for MKK4 (153).  
Regardless, in both events, there has been no discernable difference in MKK 
phosphorylation states in vivo associated with LRRK2 mutation. 
Recent studies in Drosophila initially indicated that 4E-BP (eukaryotic initiation factor 
4E (eIF4E)-binding protein) was a potential substrate for LRRK2 (157, 308).  eIF4E 
binds to capped mRNA species and promotes their translation, while binding of 4E-BP 
inhibits eIF4E and therefore represses translation (334).  In this vein, LRRK2 would 
phosphorylate 4E-BP (at T37/T46), which would then recruit other kinases to 
phosphorylate the protein at secondary sites (S65/S70) thereby activating 4E-BP and 
repressing translation (130).  Recently, Kumar and colleagues attempted to replicate the 
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phosphorylation of 4E-BP by LRRK2, and found that levels of 4E-BP phosphorylation 
were extremely weak, even lower than autophosphorylation of LRRK2 (187).  
Furthermore, they showed that the 4E-BP phosphorylation state in HEK cells stably or 
transiently expressing LRRK2 is unaffected.  Therefore, the authenticity of 4E-BP as a 
physiological kinase substrate remains in question. 
Qing and colleagues recently proposed that alpha-synuclein is phosphorylated by LRRK2 
at S129 (267).  As mentioned previously, alpha-synuclein is known to be phosphorylated 
in LBs, and some studies suggest that phosphorylation at S129 is the dominant 
modification in LBs (9, 95, 125).  Unfortunately, we and many other groups have been 
unable to replicate this finding.  The original study relied on crude cellular extracts which 
may contain a number of contaminating kinases known to phosphorylate synuclein at 
S129 (casein kinase-2, G-protein coupled receptor kinase-2,-5 and polo-like kinases), and 
they failed to provide a kinase-dead version of LRRK2 to bolster confirmation of direct 
phosphorylation of alpha-synuclein.  Like 4E-BP, the validity of alpha-synuclein as a 
direct substrate for LRRK2 is questionable at best. 
4.3  ROC Activity: GTP Binding and GTPase Activity 
The ROC domain of LRRK2 shares closest sequence homology to the Ras/Rab-related 
small GTPase family (219).  This subfamily of GTPases is known to be involved in cell 
growth, differentiation, vesicle and membrane trafficking, vesicle formation, and 
membrane fusion (122, 303, 304).  These GTPases are generally activated by the binding 
of GTP and deactivated by its subsequent hydrolysis to GDP, a process facilitated by 
guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs), respectively 
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(17, 30).  Due to the requirement of these GEFs and GAPs, measuring GTP/GDP binding 
and GTPase activity in vitro can be difficult.  The first study to examine LRRK2 guanine 
nucleotide binding and enzymatic activity metabolically labeled transiently transfected 
non-neuronal (HEK 293) and neuronal (Neuro-2A) cells (159) and found that LRRK2 
was capable of binding both GTP and GDP; however, LRRK2 recovered from cells 
persisted only in the GTP bound state.  While the majority of GTPases usually exist in 
the GDP-bound state, there are a few that remain preferentially bound to GTP (e.g. Di-
Ras) (182).  Deficiencies in GTPase activity usually account for preferential binding to 
GTP, and here, it was concluded that LRRK2 lacked the ability to hydrolyze GTP.  
Subsequent studies of the GTPase domain found that this enzymatic activity is present, 
however it was very weak (201).  The rate limiting step was shown to be the release of 
GDP, and the kcat for the hydrolysis of was reported in two studies as ~0.025min-1 (136, 
205) and a third study at ~0.23sec-1 (210). 
Given that both the GTPase and kinase domain are active in LRRK2, it is not surprising 
that a functional link exists between the two domains.  Mutating the K1347 to A in the 
guanine nucleotide phosphate-binding loop (P-loop) prevents GTP/GDP from binding 
(201, 296, 342).  As a result of this mutation, levels of autophosphorylation and 
phosphorylation of MBP are drastically decreased, suggesting that an active GTPase 
domain (or one bound to GTP/GDP) is required for functional activity.  Conversely, 
binding of GTP or non-hydrolyzable GTP within the ROC domain stimulates LRRK2 
kinase activity (159, 296, 343). 
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Despite the ROC domain’s ability to function in the absence of an active kinase domain, 
the ROC domain itself contains several residues proposed to be constitutively 
phosphorylated and/or autophosphorylated that may affect GTPase activity: 
T1343/S1345, T1348/T1349, T1368, S1403/T1404, T1410, T1452, T1491, and T1503 
(residues in bold have been confirmed in at least two separate studies) (116, 133, 167).  
The majority of these residues cluster around the P-loop, which may indicate a possible 
role for modulation of GTPase activity by phosphorylation.  T1343 alongside R1398 
occupy structurally equivalent positions in Ras (G13 and Q61) which are known to 
interact with the gamma phosphate of GTP (70).  Similarly to inactivating mutations 
found at these residues in Ras, mutating these residues in LRRK2 (T1343G and R1398Q) 
disrupts GTP binding and results in lowered kinase activity.  Adjacent to the 
aforementioned K1347 residue in the P-loop, mutating the T1348 to N (mimicking the 
Ras S17N inactivating mutation found in a conserved S/T residue of GTPases) also 
results in the ablation of kinase activity (159).  Currently, how these phosphorylation 
sites may affect endogenous kinase activity is unknown, but this data strengthens the role 
for the GTPase domain’s regulation of LRRK2 kinase activity. 
Aside from enzymatic activity, it has also been shown that the ROC domain is sufficient 
for dimerization of truncated and full-length forms of LRRK2 (70, 134, 176, 206).  Co-
immunopreciptation of differentially tagged LRRK2, yeast two hybrid assays, native 
PAGE, and gel filtration analyses support the ability for LRRK2 to interact with itself 
and form dimeric as well as oligiomeric structures in vitro and in cell culture systems. 
Published in 2007, the crystal structure of the ROC dimer shows a complex degree of 
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interaction between the two monomers (70).  Each monomer contains 5 alpha-helices and 
6 beta-strands with loops in-between distributed through the head, neck and body 
domains.  The head domain and first half of the neck domain from one monomer interacts 
with the body domain of the other monomer.  Berger recently demonstrated that 
compared to the monomer, the LRRK2 dimer binds GTP more efficiently, has increased 
kinase activity, and is enriched in the membrane (21).  This study also found that the 
membrane-bound pool of LRRK2 had a 30% decrease in phosphorylation levels 
compared to the cytostolic pool. 
In addition to self-interaction, the Roc domain is sufficient for interaction with a variety 
of binding partners.  The carboxy terminus of HSP70-interacting protein (CHIP), which 
acts to ubiquitinate and direct LRRK2 for degradation by the proteasome (76, 179), 
interacts with LRRK2 through the ROC domain.  In addition, the ROC domain can pull 
down ribosomal binding proteins S8 and L3, as well as alpha/beta tubulin heterodimers 
(102). In primary hippocampal neurons, endogenous LRRK2 has been shown to 
colocalize with alpha/beta-tubulin colocalize in the cell body and along neuronal 
processes (102), and this finding has also been seen in HEK293 cells for beta-tubulin 
(117).  A functional interaction has been shown in-vitro through the phosphorylation of 
beta tubulin by LRRK2 (112), although this has not yet been replicated.  However, this 
same study found that LRRK2 knockout mice display a ~33% reduction in 
phosphorylated beta-tublin compared to wild-type controls.  Multiple lines of other 
evidence suggest a role for LRRK2’s interaction with the cytoskeleton.  For example, in 
cellular models of primary neurons, RNAi knock down of endogenous LRRK2 causes a 
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significant increase in process length, while disruption of the ROC domain leads to 
shortened processes (214). 
4.4  Non-Enzymatic LRRK2 Domains 
There are three defined non-enzymatic domains that have consequential effects on 
LRRK2 functionality.  Starting from the C-terminus, the first of these is the WD40 
domain.  First described in 1986, WD40 domains have been implicated in signal 
transduction, pre-mRNA processing, and cytoskeleton assembly (91, 295, 305).  The 
LRRK2 WD40 domain is a notable point of divergence between the LRRK1 homologue, 
and therefore may be critical for its unique function.  Recently, T2483 in the WD40 
domain was identified as a site of autophosphorylation (116), and deletion of this domain 
results in a loss of autophosphorylation as well as decreased phosphorylation of MBP 
(134, 156, 160, 165).  In addition, the WD40 deletion disrupts the ability of LRRK2 to 
dimerize (134, 165), while its addition to the ROC-Cor-Kinase fragment strengthens 
dimerization (134).  Deletion of the WD40 domain in the zebrafish homologue for 
LRRK2 (zLRRK2) results in loss of dopaminergic neurons in the diencephalon alongside 
defects in locomotion (286).  Aside from dimerization, the WD40 domain may also play 
a critical role in functionally linking LRRK2 to other proteins.   
LRRK2 associates with a number of membrane-bound organelles and vesicular 
membranous structures, including lipid rafts and the outer membrane of the mitochondria 
(24, 140, 342).  In yeast, another similar complex of proteins known to associate with the 
mitochondrial membrane is the Fis1.Mdv1.Dnm1 complex (240).  Dnm1 (dynamin-
related GTPase) can interact with the outer membrane of the mitochondria, but is only 
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stably retained through interaction with the WD repeat containing adaptor protein Mdv1, 
where further interaction with Fis1 triggers mitochondrial fission.  Given that LRRK2 has 
both a GTPase and WD40 repeat region, the WD40 domain may play a similar role, 
linking LRRK2 and other protein interactors at the level of the membrane. 
While a number of studies implicate the ROC domain’s ability to regulate kinase activity, 
it is unclear how this signal is transduced to the kinase domain.  When the structure of the 
ROC domain was published in 2008, there was note of a strong intrinsic interaction 
between the ROC and Cor domains, stronger than that of the ROC domain and full-length 
LRRK2 (70).  It has therefore been hypothesized that upon activation of the ROC 
domain, the Cor domain may act as a molecular hinge to facilitate the dimerization and 
subsequent autophosphorylation of the kinase domain (70, 331).  The structure of the 
highly conserved Roc-Cor domain of the C. tepidum prokaryotic homologue of LRRK2 
was published in 2008 and showed that this region contained two subdomains connected 
by a long, slightly flexible single polypeptide chain (127).  This study proposed that 
instead of the ROC domain, dimerization is facilitated through the COR domains’ 
interaction at its C-terminal subdomains.  In this formation, the ROC domains partake in 
a more freely mobile state. 
In addition to dimerization, the Cor domain has been implicated in an interaction between 
LRRK2 and Parkin (297).   Co-expression studies of these two proteins in HEK293T 
cells show that both proteins CO-IP with each other, and this interaction is facilitated 
through the Cor domain of LRRK2 and the RING2 domain of parkin.  Co-expression also 
resulted in an increase in cytoplasmic aggregates that contain LRRK2 and enhanced their 
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ubiquitination; however, unlike CHIP, there is no direct evidence that parkin is involved 
in the ubiquitination of LRRK2.  It is unclear why the amount of ubiquitinated aggregates 
increased, however the coexpression of LRRK2 increased the autoubiquitination activity 
of parkin 25-fold, which may lead to the overall stimulation of the ubiquitin proteasome 
pathway. 
While few functional findings have been reported for the leucine-rich repeat (LRR) 
region of LRRK2, Shin and colleagues discovered that this portion of the protein interacts 
with Rab5b (288).  Rab5b is a small GTPase involved in synaptic function by modulating 
endocytosis of synaptic vesicles (202).  Its interaction with LRRK2 is isoform specific as 
neither Rab5a nor Rab5c interact with the protein.  Both proteins were detected in the 
soluble synaptosome fraction (although LRRK2 was also found in the cytosol and other 
membrane fractions) in rat cortex, and both proteins co-localized in the cell body and 
neurites as well as with presynaptic vesicle markers (synaptobrevin-2, synaptophysin) in 
rat hippocampal neurons.  Functionally, LRRK2 overexpression causes a decrease in the 
rate of synaptic vesicle endocytosis, and this effect can be rescued by the expression of 
both wildtype and a constitutively active Rab5b, but not a dominant negative form. 
Deletion of the LRR region does not appear to affect localization of transiently expressed 
LRRK2 in SH-SY5Y cells, however it does prevent toxicity by disrupting its ability to 
induce caspase 3 activation and nuclei condensation (156).  In vitro kinase activity is not 
affected by the loss of this domain, and so presumably this effect is mediated by the LRR 
region’s direct interaction with signaling partners in the apoptotic cascade.  These 
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interactions may be regulated by a narrow stretch of serine residues directly preceding the 
LRR region, which is a site of high constitutive phosphorylation (116). 
5. Mutations in LRRK2 and its Link to PD 
Autosomal dominant missense mutations in the gene for LRRK2 are the most common 
known cause of PD (110, 249, 355). Over 75 sequence variations have been identified in 
LRRK2, of which at least 5 missense mutations are considered definitely pathogenic 
(R1441C/G, Y1699C, G2019S, and I2020T), and 2 others are considered increased risk 
factors for disease (R1628P, G2385R) (60).  Understanding how these mutations lead to 
the dysfunction of LRRK2 may shed new light on potential pathways in the progression 
of PD. 
5.1  The Pathology of Cases with LRRK2 Mutation 
To date, a relatively low number of cases have come to autopsy with mutations in 
LRRK2.  A wide range of pathological phenotypes have been reported in these patients, 
ranging from classic degeneration of the SN with traditional Lewy pathology similar to 
presentation in idiopathic cases of PD, to pure nigral degeneration with a lack of Lewy 
pathology and the presence of tau neurofibrillary tangles (NFTs) (56, 62, 96, 98, 99, 105, 
111, 113, 172, 222, 269, 276, 346, 347, 355).  These varying pathologies are even present 
with patients who carry the same mutation (Figure 1-4): in three patients with the 
G2019S mutation, two (Patient A and B) demonstrated classic PD with LBs, while the 
third (Patient C) had a paucity of Lewy pathology.  Patient A also displayed LBs in the 
limbic cortex, while patient B had concurrent neocortical senile plaques and occasional 
NFTs (105).  
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Figure 1-4. Histological characterization of patients with LRRK2 mutations. (A, B) Staining for alpha-
synuclein in the SNpc of Patient A using antibody Syn 505 demonstrating the presence of classic LBs 
(arrow) and cytoplasmic alpha-synuclein inclusions (arrowheads) in dopaminerginergic neurons containing 
neuromelamine. An alpha-synuclein spheroid is indicated by an asterisk in B. (C) Cortical LBs stained with 
anti–alpha-synuclein antibody Syn 505 in the cingulated cortex of Patient A. (D) A neurofibrillary tangle 
(NFT) (arrow) and tau-positive dystrophic neurites within a senile plague (SP) in the hippocampus of 
Patient B stained with anti–tau antibody 17026. (E) The staining pattern of LRRK2 depicted with rabbit 
anti–LRRK2 antibody AP7099b. Note the intense staining in Purkinje neurons and their processes. (inset) 
Immunofluorescence analysis showing the cytoplasmic pattern of HA-tagged LRRK2(1245-2527) 
expressed in HEK293T (green) and DAPI staining of the nuclei (blue). (F, G) Dystrophic neurites in the SN 
of Patient C displaying accumulation of LRRK2 as stained with the rabbit anti–LRRK2 antibody. Scale bar 
= 40μm.  Figure from Giasson et al (105).  
A paucity  of Lewy pathology has been reported in 1  out of  17 additional  G2019S cases 
(99, 269), 6 of the 8 autopsied patients from the Hasegawa and Kowa Japanense kindred 
with the I2020T mutation (97, 139), the only R1441G (Basque) case autopsied (222), 2 of 
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the 4 R1441C cases from the Canadian family D (74, 142, 346, 355), and 2 of the 4 
Y1699C cases (172, 355).  The additional neuropathological findings for these atypical 
cases have been mixed.  For the 2 Y1699C cases, amyotrophy in addition to 
parkinsonism was observed, and there was a presence of “ubiquitin-positive” cytoplasmic 
and nuclear inclusions (355).  For the R1441C mutations carried within the Canadian 
family D, one of the documented cases presented tau pathology reminiscent of 
progressive supranuclear palsy while another displayed nonspecific loss of dopaminergic 
neurons with ubiquitin-positive inclusions in the absence of Lewy pathology (346, 355). 
Despite the pleomorphy of pathological inclusions observed throughout the literature, all 
cases report degeneration of the SN. 
 Given studies showing that LRRK2 forms aggregates in some cellular models (131, 
297), several laboratories began examining LRRK2’s presence in LBs (4, 131, 148, 234, 
235, 269, 353).  In our initial 2006 study of the 3 G2019S patient described above, no 
LRRK2 staining of LBs was observed, nor was LRRK2 found in brain Lewy inclusions 
from an additional 80 patients with either classic PD (46 cases) or DLB (34 cases).  
Shortly thereafter, Zhu and colleagues published a letter indicating that LRRK2 could be 
found in LBs when using two newly designed antibodies by Novus Biologicals (354).  
We tested these antibodies and found that their specificity was lacking (Figure 1-5), and 
concluded the staining of LBs could be non-specific (55); other laboratories have 
corroborated these results (280).  Because we cannot account for batch differences among 
commercial antibodies, we designed and developed our own. We engineered three 
antibodies, one monoclonal and two polyclonal, which were very specific for the LRRK2 
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protein.  Using these antibodies, again, a paucity of staining was observed for LRRK2 in 
LBs (340).  Regardless, a handful of studies have used the nonspecific antibodies 
mentioned above to ascribe the inclusion of LRRK2 in LBs (4, 131, 148, 234, 235, 269, 
353); however, staining is inconsistent and therefore inconclusive.  It remains to be seen 
whether LRRK2 is truly a component of Lewy pathology, but our studies indicate that it 
is not. 
 
Figure 1-5. Characterization of LRRK2 antibodies. A. Schematic of LRRK2 and its 
associated domains with antibodies AT106 (Alexis Biochemicals, San Diego, CA), NB 
300-267 (Novus Biologicals, Littleton, CO), NB 300-268 (Novus Biologicals), and 
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AP7099b (Abgent, San Diego, CA) listed above their epitopes for LRRK2.   B. 
Immunoblot analyses of high-salt extracts from the brain cortex of two healthy 
individuals, (Hu-1 and Hu-2) and mouse cortex (Mo), and a RIPA-soluble extract from 
HEK293T cells with various LRRK2 antibodies. Antibody AP7099b detects full-length 
Lrrk2 with mobility of ~250kDa, as well as a ~130kDa breakdown product, which is due 
to postmortem degradation. AT106, NB 300-267, and NB 300-268 detect a variety of 
immunobands, but none that corresponds to full-length LRRK2.  Figure adapted from 
Covy and Giasson 2006 (55). 
Mixed pathologies have also been reported in various in vivo models.  In LRRK2 
knockout mice, no aberrant brain neuropathology has been found up to 2 years of age 
(10, 68, 209, 323); however, significant effects have been observed in the kidney where 
LRRK2 is normally expressed at high levels (~6-fold compared to the brain) (323).  Loss 
of LRRK2 within the kidney leads to an age-dependent increase in markers of autophagic 
dysfunction (LC3-II, p62) and apoptotic cells (activated caspase-3, TUNEL positive 
cells) alongside the accumulation (60-fold over wild-type) and aggregation of alpha-
synuclein and other ubiquitinated proteins.  Conversely, in the brains of A53T alpha-
synuclein transgenic mice, which normally develop an age-dependent fragmented Golgi 
apparatus in neurons that correlates with an increase in the somatic accumulation of 
alpha-synuclein, genetic ablation of LRRK2 serves a protective role by preventing these 
abnormalities, while transgenic expression of human LRRK2 exacerbates the phenotype 
(209).  Conflicting pathology has also been found in Drosophila models. It was first 
reported that the loss of dLRRK (the Drosophila orthologue for both LRRK1 and 
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LRRK2) resulted in severely impaired locomotor activity and reduced tyrosine 
hydroxylase (TH) immunoreactivity of DA neurons (195).  Shortly thereafter, a handful 
of studies reported that loss of dLRRK had no effects on TH immunoreactivity of DA 
neurons, however overexpression of dLRRK, human LRRK2, or their mutant forms can 
cause dopaminergic neuron degeneration and locomotor dysfunction (157, 211, 242, 
332). 
5.2  LRRK2 Kinase Domain Mutations are the Most Prominent Cause of PD 
The I2020T mutation within the kinase domain was among the earliest missense 
mutations identified in LRRK2 (97).  Soon thereafter, additional mutations were found, 
including the most prevalent mutation just adjacent to this residue: G2019S (166).  The 
G2019S mutation is reportedly responsible for 0.6-1.6% of sporadic PD and 2-8% of 
familial PD cases (50). In certain ethnicities, such as North African Arabs and Ashkenazi 
Jews, the G2019S mutation is an even greater factor contributing to PD (22-41% of 
individuals with disease) (198, 199, 248).  A large case-control study from 2008 found 
that the G2019S accounts for more than 85% of patients carrying a mutation within 
LRRK2 (141).  Given that the pathological G2019S mutation lies within the activation 
loop of the kinase domain, much attention has been directed towards understanding how 
aberration of kinase activity may lead to disease. 
5.3  The Common G2019S Pathological Mutation Increases Kinase Activity 
Initial in-silico studies suggested that the G2019S mutation may increase LRRK2 kinase 
activity (3). Given that no nonsense mutations of the protein had been identified, this 
model coincided nicely with a gain-of-function for LRRK2.  Indeed, the overwhelming 
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majority of studies on LRRK2 kinase activity show that the G2019S mutation increases 
activity around 2-3 fold over wild-type (130). 
G2019 is part of the highly conserved DFG motif in the VII subdomain of the kinase 
region (138, 168), and the D residue in this motif is involved in Mg2+ binding and proper 
coordination of ATP-Mg2+ in the active site (67, 170, 200, 315).  The DFG motif is 
located at the N-terminal hinge region of the activation loop that switches from an open 
and extended conformation in the active state to a more closed conformation in the 
inactive state (67, 168, 315), and this G residue is thought to play an important role in 
inducing proper orientation of the D residue (183).  After inactivation, the G residue 
usually performs an extreme twist which disrupts its hydrogen bond to the D residue, 
thereby facilitating this D residue to also to turn away from the catalytic site. The lack of 
a side chain is thought to allow the G residue to make this turn with little steric hindrance.  
The G2019S mutation may disrupt the ability of this movement, and could keep the D 
residue positioned in the active site for longer activation periods that may also contribute 
to a greater catalytic rate. 
5.4  LRRK2 Kinase Activity is Linked to Neurotoxicity 
While the majority of studies agree that the most common G2019S mutation increases 
kinase activity, the effect of other pathological LRRK2 mutants remains unclear.  For the 
I2020T mutation, some studies report a modest increase (117, 157, 212, 343), a slight 
decrease (160, 244), or no change in activity (7, 213).  In our hands, this mutation slightly 
increases activity of the full-length protein (54).  Mixed information has also been 
reported for the R1441C, and Y1699C mutation (7, 54, 131, 132, 136, 160, 214, 296, 
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342, 343).  A caveat to these results is the wide range of techniques used: from the type 
of substrate (autophosphorylation, generic proteins, synthetic peptides), to the assay 
conditions (reaction temperatures, indirect phosphorylation, chosen cofactors), and even 
the form of LRRK2 utilized (bacterially expressed, endogenously purified, truncated 
versions).  As a result, it’s difficult to interpret the varied effects on kinase activity; 
however, it is still possible to examine the role the kinase domain plays in LRRK2 
toxicity.  
The earliest in vivo studies on the toxic effect of the G2019S were reported in Drosophila 
when expressing the human form of LRRK2 (hLRRK2), however mixed results have 
been reported for studies utilizing mutant dLRRK knockins as well as knock-outs.  These 
inconsistencies in Drosophila (as well as those seen for C. elegans models) must be 
approached with caution because the single LRRK gene is not a true orthologue of the 
human LRRK genes (220):  similarity in hLRRK2 and dLRRK is only 38–44% (332).   
While no overt pathological phenotype has been found in G2019S LRRK2 transgenic 
mice up to 24 months of age, disruptions in striatal dopamine transmission have recently 
been identified (204, 231, 338).  G2019S LRRK2 transgenic mice show an age-
dependent decrease in release, uptake, and overall content of straital dopamine. In 
addition, G2019S LRRK2 may cause age-dependent hyperphosphorylation of tau.  In 
G2019S LRRK2 BAC transgenic mice aged 18–24 months, hyperphosphorylated tau at 
S202/T205 and S262/S356 was observed in mice only after 6-12 months of age (233).  
However, an earlier study found no changes in tau phosphorylation at S202/T205 and 
S396/S404 (204), but both studies found a modest increase in tau phosphorylation when 
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overexpressing wild-type LRRK2.  Despite these contrasting effects, rat cortical neurons 
transfected with G2019S or I2020T LRRK2, but not wild-type LRRK2 contained 
spheroids in neuronal processes that stained positive for phosphorylated tau at S202 
(214).  These studies illustrate a possible connection between aberrant kinase activity and 
tau phosphorylation in vivo. 
In both neuronal cell lines and primary neuronal cultures, wild-type LRRK2 forms 
aggregates in a small proportion of cells, and several pathogenic mutations (I1122V, 
R1441C, Y1699C, G2019S, and I2020T) have been shown to increase its propensity to 
aggregate (131, 297).  When expressed in COS-7 cells, LRRK2 aggregates colocalize 
with gamma-tubulin and are surrounded by vimentin, although not reactive for Lamp-1 
(340).  In addition, blocking the proteasome with MG132 increases the frequency and 
size of LRRK2 aggregates, while treatment with the microtubule depolymerizing agent 
nocodozole breaks up these large aggregates (Figure 1-6), suggesting these are the result 
of aggresome formation.   
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Figure 1-6.  LRRK2 aggregates in transfected COS-7 cells.  Double immunofluorescence was 
performed with a monoclonal anti-V5 antibody (red) and rabbit anti-LRRK2 antibody 1181#1 (green) in 
COS-7 transfected with LRRK2-V5. (A) Rare large aggregates were observed under basal conditions at 48 
hours post-transfection. (B) Sixteen hours of MG132 (10µm) treatment induced aggregate formation. (C) 
MG132 treatment with concomitant nocodazole prevented the formation of large, perinuclear aggregates. 
Small aggregates throughout the cytosol were noted with nocodazole treatment (inset). Images are 
representative of 3 independent experiments. Bar scale: 50µm; inset 25µm.  Figure from Waxman et al 
2009 (340). 
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In addition to protein aggregation, LRRK2 pathogenic kinase domain mutations can also 
cause neurodegeneration consistent with mitochondrial-dependent apoptotic cell death.  
In rat primary cortical neurons, overexpression of the pathological G2019S and I2020T 
LRRK2 mutants, but not wildtype LRRK2, leads to a progressive reduction of branching 
and neurite outgrowth, and decreased cell survival marked by elevated levels of activated 
caspase 3 (214).  Reductions in neurite outgrowth have also been shown in primary 
neurons from G2019S LRRK2 transgenic mice (338), and caspase 3 activation by mutant 
forms of LRRK2 was replicated in a similar study using SH-SY5Y cells.  Here, LRRK2 
caused the release of cytochrome c, and was dependent on Apaf1 for caspase 3 activation 
(156).  Another study found that LRRK2 can mediate apoptotic cell death through 
interaction with the death adaptor protein FADD to recruit and activate caspase 8 (150).   
There may also be an autophagic component of LRRK2 mediated cell toxicity.  Alegre-
Abarrategui and colleagues utilized a specialized BAC-vector expressing the LRRK2 
locus at low physiological levels in HEK293-FRT cells to identify the recruitment of 
LRRK2 to specific membranous microdomains within multivesicular bodies (MVBs), as 
well as to autophagic vacuoles (AVs) (5).   Autophagic degradation of organelles can also 
be found in pre-differentiated SH-SY5Y cells overexpressing G2019S LRRK2 in both 
neuritic and somatic compartments (214). RNAi knockdown of components of the 
autophagy system (LC3 or Atg7) prevent these effects of G2019S LRRK2 on neuronal 
process length and toxicity, while treatment with an autophagy enhancing drug 
(rapamycin) potentiates its effect (260). 
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The aberrant effects of the pathogenic mutants of LRRK2 appear to be directly regulated 
by and/or dependent on an active kinase domain.  Introducing amino acid substitutions 
that disrupt kinase activity (i.e. knocking out the ATP binding domain, metal cation 
binding motif, or proton acceptor site) into pathological LRRK2 mutants reduce the 
number of LRRK2 aggregates back towards levels of the wildtype protein (131, 297).  
More importantly, in all models of LRRK2-mediated cell death discussed above, 
inactivating the kinase domain negates all effects of mutant LRRK2 toxicity: neurite 
branching and outgrowth is restored, markers of autophagic degradation are no longer 
observed, enhanced binding of FADD is disrupted, and caspase activation is inhibited. 
The dependence of all these effects on functional kinase activity highlights the critical 
role this domain plays in facilitating the deleterious effects of LRRK2. 
5.5  Mutations Outside of the Kinase Domain can Affect Kinase Activity 
Outside of the kinase domain, the most prominent region where mutations are observed is 
the ROC domain.  As previously mentioned, the ROC domain is an enzymatically active 
GTPase, in which the GTP bound form has a stimulatory effect on kinase activity.  
Various mutations have been reported within this region; however the most notable is at 
R1441.  The ROC domain is capable of binding with itself, and is sufficient to pull down 
full-length LRRK2; an interaction that is disrupted by the pathogenic R1441C mutation 
(206).  As the ROC domain dimerizes, this R residues sits between the interacting surface 
of the two monomers (70), and its mutation may disrupt the stability of the ROC dimer 
and subsequent enzymatic activity.  Indeed, several studies have shown that pathogenic 
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ROC mutations decrease GTPase activity, prolonging the protein in the GTP-bound state 
(136, 201, 205). 
Given that ROC mutations prolong the GTP-bound state of LRRK2, one would assume 
that this mutation would result in increased kinase activity.  However, as discussed 
above, the experimental data on kinase activity has been mixed.  A caveat to the 
discrepancy may revolve around the expression and purification methodology of LRRK2.  
Multiple studies have shown that intrinsic GTPase activity of the protein is weak, and 
LRRK2 purified in the presence of nonhydrolyzable GTP displays increased kinase 
activity compared to LRRK2 purified without (159, 205, 296, 343).  The R1441C 
mutation may in fact prolong the more active GTP-bound state of LRRK2, however, if 
the protein does not have access to the necessary GEFs (or is overexposed to particular 
GAPs) required for proper GTP binding, it may explain some of the discrepancies.  
A model of decreased GTPase activity by the mutation at R1441 leading to increased 
kinase activity adheres to the similar results observed in cellular models for LRRK2 
toxicity.  As with the G2019S and I2020T mutants, R1441C/G LRRK2 induces caspase 3 
in an Apaf1 dependent manner, decreases neurite length and branching, and coincides 
with markers of autophagic degradation (156, 214).  Furthermore, inactivating the kinase 
domain disrupts all toxic effects of R1441C/G LRRK2 mutations, strengthening the 
theory that kinase activity is required for the neurodegenerative effects of pathological 
LRRK2.  In vivo, R1441 LRRK2 transgenic mutations recapitulate similar symptoms of 
the G2019S LRRK2 mutant, as R1441C LRRK2 knock-in mice (322) and R1441G 
LRRK2 BAC transgenic (207) mice both show deficits in dopamine release.  In addition, 
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the SNpc of R1441G LRRK2 transgenic mice have a decrease in TH immunoreactive 
dendrites as well as a decrease in average cell body size. 
The WD40 domain also appears to have a direct effect on kinase activity, and as a result, 
the neurotoxicity of LRRK2.  Like the kinase-inactive form, mouse primary cortical 
neurons transfected with LRRK2 pathological mutants lose their toxic effect if the WD40 
domain is deleted (156).  Examining these constructs in-vitro reveals that removal of the 
WD40 domain results in disruption of LRRK2 dimerization, and a loss of 
autophosphorylation (165).  Not only is this domain required for kinase activity and 
neurotoxicity, the R2385G LRRK2 mutation found in this region results in an increased 
risk for developing PD and has recently been shown to have a slight activating affect on 
kinase activity (~1.5 fold) (310).  Interestingly, this mutation has a high prevalence in 
Han Chinese (4-8%), while the G2019S mutation has yet to be found (6, 310, 311). 
6. Scope of this Research 
The identification of genetic factors causal for PD has provided a valuable opportunity to 
gain much needed insight into the etiology of this disease.  Mutations in the gene for 
LRRK2 are the single most common known cause of both familial and sporadic forms of 
PD; however, the understanding of this protein’s function is still rudimentary and it 
remains unclear how aberration of LRRK2 leads to disease.   The followings aims were 
developed to address these issues which represent the scope of this thesis research: 
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Research Aim I 
Screen for mutations of LRRK2 in patients with PD and DLB, and characterize their 
neuropathological consequences. 
Research Aim II 
Develop an in-vitro model of LRRK2 kinase activity to assess the effects of pathogenic 
mutations and identify compounds that can inhibit substrate phosphorylation. 
Research Aim III 
Determine a possible mechanism for the greater pathogenicity of the G2019S LRRK2 
mutant versus other LRRK2 pathogenic mutations. 
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CHAPTER TWO 
 
CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF 
PATIENTS WITH LEUCINE-RICH REPEAT KINASE 2 
MUTATIONS 
 
 
 
 
 
Data from this chapter was published in: 
Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI (2009).  
Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 
mutations.  Mov Disord. 24; 32-9 
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ABSTRACT 
Mutations in LRRK2 are the single most common known cause of Parkinson’s disease 
(PD). Two new PD patients with LRRK2 mutation were identified from a cohort with 
extensive post-mortem assessment. One of these patients harbors the R793M mutation 
and presented with the typical clinical and pathological features of PD. A novel L1165P 
mutation was identified in a second patient. This patient had the classical and 
pathological features of PD, but additionally developed severe neuropsychological 
symptoms and dementia associated with abundant neurofibrillary tangles in the 
hippocampal formation; features consistent with a secondary diagnosis of tangle-
predominant dementia. α-Synuclein-containing pathological inclusions in these patients 
also were highly phosphorylated at S129, similar to other patients with idiopathic PD. 
These two PD patients also were characterized by the presence of occasional cytoplasmic 
TDP-43 inclusions in the temporal cortex, a finding that was not observed in three other 
patients with the G2019S mutation in LRRK2. These findings extend the clinical and 
pathological features that may be associated with LRRK2 mutations. 
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INTRODUCTION 
Parkinson’s disease is the second most common neurodegenerative disease in the 
developing world and is characterized by bradykinesia, resting tremor, cogwheel rigidity 
and postural instability (104, 292).  These major clinical features of PD are associated 
with the loss of dopaminergic neurons in the SNpc (63, 252).  In addition, postmortem 
analysis of the majority of clinically diagnosed PD patients reveals intracytoplasmic 
inclusions known as LBs and LNs in some of the remaining dopaminergic neurons. LBs 
and LNs are formed as the result of the aberrant aggregation of the presynaptic protein 
alpha-synuclein.  These inclusions can also accumulate in other brain regions in PD as 
well as other related neurological disorders (33, 93, 119). The presence of these 
inclusions is a criterion used to differentiate PD from other disorders associated with 
parkinsonism (92, 93). 
Autosomal dominant mutations in the gene for leucine-rich repeat kinase 2 (LRRK2; also 
known as PARK8) have been identified in a significant percentage of late-onset PD cases 
(250, 355). Five missense mutations with definite pathogenicity and many other missense 
mutations that are potentially pathogenic or may act as risk factors have been reported 
(314). G2019S, the most common mutation, is reportedly responsible for 0.6-1.6% of 
sporadic (69, 111, 166) and 2-8% of familial cases of PD (69, 73, 145, 166, 245, 251). In 
some specific ethnicities such as North African Arabs and Ashkenazi Jews, the G2019S 
mutation is linked to a much higher percentage (22-41%) of patients diagnosed with PD 
(198, 199, 248). In addition, the penetrance for this mutation increases with age from 15-
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17% at the age of 50 years to 32-100% at the age of 80 years depending on the reported 
cohort (124, 166, 199). 
LRRK2 is a large 2527-amino acid protein with several distinct domains: Leucine-rich 
repeat (1010-1287), GTPase (1335-1504), COR (1517-1843), kinase (1875-2132) and 
WD40 repeat (2231-2276) (Fig. 2-1A) (355). The understanding of the biological 
function of LRRK2 is still rudimentary.  The majority of patients with LRRK2 mutations 
present with classical PD with LBs (105, 111, 254, 276), but some have Parkinsonism 
without Lewy pathology (97, 99, 105), and diverse clinical and pathological findings 
have also been reported in others (269, 347, 355). Hence, the clinical and pathological 
features of two patients, one patient with the R793M mutation and another with a novel 
L1165P mutation in the Leucine-rich domain, are described. 
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Figure 2-1. Identification of patients with LRRK2 mutations and sequence alignment of amino acids 
surrounding the mutations. (A) Schematic representation of the LRRK2 protein with major domains. The 
locations of the R793M, L1165P, and the most common G2109S mutation are indicated. Abbreviations 
used: LRR, leucine-rich repeat like domain; ROC, Ras of complex; COR, C-terminal of Roc. (B) Portion of 
sequencing electropherogram showing the region of LRRK2 exon 25 in which the heterozygous 
c.3494T>C, p.L1165P was identified in Patient E compared to normal sequence. The mutation is near the 3' 
end of exon 25.  The exon/intron junction is indicated by the dashed line. (C) Cross-species alignment of 
the amino acid sequence surrounding residue L1165. (D) Cross-species alignment of the amino acid 
sequence surrounding residue R793.  
MATERIALS AND METHODS 
Antibodies 
Murine anti-α-synuclein monoclonal antibodies LB 509, Syn 514 and Syn 211 were 
previously described (13, 79, 108). SNL-4 is a purified rabbit polyclonal antibody raised 
against a peptide corresponding to amino acid residues 2-12 in α-synuclein (108).  pSyn 
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129a is novel mouse monoclonal antibody specific for α-synuclein phosphorylated at 
S129 (340). Antibody 17026 is a rabbit antiserum raised against full-length recombinant 
tau that detects all isoforms of tau.  AP7099b is an affinity purified rabbit antibody to 
LRRK2 raised against the peptide RVEKLHLSHNKLKEIPPEIG  (Abgent, San Diego, 
CA) (105). Anti-TAR-DNA-binding protein 43 (TDP-43) rabbit polyclonal antibody was 
purchased from ProteinTech Group (Chicago, IL). 
Molecular Genetic Analysis of LRRK2 
Genetic analysis of LRRK2 was performed in a large cohort of neurodegenerative disease 
clinical and autopsy cases, including 98 cases (78 autopsied) with PD or DLB as 
previously described (43). Single nucleotide polymorphism (SNP) genotyping using 
TaqMan chemistry-based allelic discrimination assay with “Assay by Design” (Applied 
Biosystems, Foster City, CA) probes on an Applied Biosystems 7900 was performed for 
the LRRK2 mutations: G2019S, I2020T, M1869T, R793M, and Y1699C. Appropriate 
positive and negative controls were used and data was analyzed using Sequence 
Detection System 2.2.1 software (Applied Biosystems) as described (88). In the PD and 
LB autopsy cases, bi-directional DNA sequencing of a 251 bp product containing exon 
25 was used to evaluate for the presence of the I1122V mutation which also allowed for 
the identification of a novel c.3494T>C, p.L1165P (Fig. 1B) variant within the exon 25 
region as described (43).  All cases with LRRK2 mutations were confirmed by bi-
directional DNA sequencing using standard methods on a CEQ8000 (Beckman Coulter).   
To evaluate the novel exon 25 mutation c.3494T>C, p.L1165P, a TaqMan “Assays by 
Design” allele discrimination assay was developed and performed on 366 control 
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samples. The control samples were obtained from the following sources: 276 controls 
from the Coriell Institute (Neurologically Normal Caucasian control panels, Camden, 
NJ), 48 clinical controls (mean age 76) from the Alzheimer Disease Center at the 
University of Pennsylvania, and 42 brain autopsy samples (mean age 69) with normal 
pathology from the University of Pennsylvania Center for Neurodegenerative Disease 
brain bank.  All research activities were approved by the University of Pennsylvania 
Institutional Review Board and all participants gave informed consent. 
Immunohistochemistry and Immunofluorescence  
The harvesting, fixation and further processing of the tissue specimens were conducted as 
previously described (78). Briefly, tissue blocks were removed at autopsy and fixed by 
immersion in 70% ethanol with 150mM/L NaCl or 10% buffered formalin for 24-36 hr. 
Samples were dehydrated through a series of graded ethanols to xylene at room 
temperature and infiltrated with paraffin at 60ºC as previously described (78). Tissue 
blocks were then cut into multiple, near serial 6μm sections for immunohistochemical 
staining. 
Immunohistochemistry was carried out using the avidin-biotin complex (ABC) detection 
system (Vector Laboratories, Burlingame, CA) and 3,3’-diaminobenzidine as described 
previously with some modifications (78). Briefly, sections were deparaffinized and 
sequentially rehydrated using 100-70% ethanol followed by water. Some sections were 
pretreated with 88% formic acid to enhance antigen detection. Endogenous peroxidases 
were quenched with 5% hydrogen peroxide in methanol for 30 min and sections were 
blocked in 0.1M Tris with 2% fetal bovine serum (Tris/FBS) for 5 min. All antibodies 
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were diluted in Tris/FBS. Primary antibodies were incubated overnight at 4ºC. After 
washing, sections were sequentially incubated with biotinylated secondary antibodies for 
1 hr and ABC complex for 1 hr. Bound antibody complexes were visualized by 
incubating sections in solution containing 100mM Tris, pH 7.6, 0.1% Triton X-100, 
1.4mM DAB, 10mM imidazole, and 8.8mM hydrogen peroxide. Tissue sections were 
lightly counterstained with hematoxylin.   
For immunofluorescence, tissue sections were re-hydrated and incubated with primary 
antibodies as described above.  After washing, anti-mouse or anti-rabbit secondary 
antibodies conjugated to Alexa Fluor 488 and 594 secondary were applied (Molecular 
Probes, Eugene, OR). Following washing and post-fixation with formalin, sections were 
cover-slipped with Vectashield with 4'-6-diamidino-2-phenylindole mounting medium 
(Vector Laboratories, Burlingame, CA).   
RESULTS 
Genetic Analysis of LRRK2: 
Among the 98 sporadic and familial PD patients screened, 4 (~4%) were identified with 
the G2019S mutation (3 heterozygous and 1 homozygous). Of these, the clinical and 
pathological findings for three cases have been previously reported,(105) while the fourth 
was a living patient with onset of PD at age 44, a strong family history of PD, and a 
homozygous G2019S mutation.  Additionally, the p.R793M (c.2378 G>T) mutation was 
identified in 1 PD case (described further below as Patient D).  The I2020T, M1869T, 
and Y1699C mutations were not identified.  DNA sequence analysis of exon 25 did not 
identify any I1122V mutations; however, the novel missense mutation in exon 25 
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(c.3494T>C, p.L1165P) (Fig. 2-1B) was identified in one PD case (described further 
below as Patient E).  The L1165P mutation was absent from 366 controls tested using 
TaqMan SNP analysis. Thus, overall, 5 cases with LRRK2 mutations were found in the 
cohort of autopsies PD and DLB patients (5/78, 6.4%).   
Clinical and Pathological Findings in Cases Harboring the R793M and L1165P 
Mutations in LRRK2: 
Patient D: Patient D is a woman that first manifested unexplained falls at the age of 77.  
Within one year, clear evidence of Parkinsonism had developed, and she was started on 
carbidopa/levodopa therapy for relief of rest tremor, rigidity and general bradykinesia. 
She responded well to treatment in the early years of her illness, but she developed 
slowly progressive disability and died 15 years after onsest at 92.    
At autopsy, the SN and the locus coeruleus (LC) were severely depigmentated, but other 
brain regions were unremarkable. Detailed histological analysis revealed abundant LBs, 
LNs and α-synuclein immunoreactive spheroids in the SNpc (Fig. 2-2A, B), other brain 
stem nuclei, the hippocampus and the amygdala (Fig. 2-2C), but these inclusions were 
only sparsely present in the neocortex (Fig. 2-2D) with a distribution characteristic of 
PD.(33, 93, 119) Neurofibrillary tangles (NFTs) and tau-positive dystrophic neurites 
were moderately abundant in the hippocampal formation (Fig. 2-2E), but rare in other 
brain regions.  Senile plaques (SPs) were rare in all brain regions. No inclusions were 
detected with antibodies specific to LRRK2. 
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Figure 2-2. Histological characterization of patients with LRRK2 mutations. (A, B) Staining for α-
synuclein in the SNpc of patient D demonstrating a dopaminergic neuron with multiple LBs (A) or a typical 
spheroid (B). (C) Abundant LBs and LNs in the amygdala of patient D. (D) Cortical LBs in the cingulated 
cortex of patient D. (E) NFTs and tau-positive dystrophic neurites in the hippocampus of patient D. (F) A 
classical LB in a dopaminergic neurons in SNpc of patient E. (G) Abundant LBs and LNs in hippocampus 
of patient E. (H, I) NFTs and tau-positive neurites in the hippocampus and enterhinal cortex, respectively, 
of patient E. Tissue sections were stained with the following antibodies: anti-α-synuclein antibody Syn 514 
(A, C, D, and G), anti-α-synuclein antibody Syn 211 (B), anti-α-synuclein antibody LB509 (F), and anti-
tau antibody 17026 (E, H and I).  Scale bar = 25 µm in A, B, D, E, F, and 50 µm in C, G, H, and I. 
Patient E:  This man developed the first signs of Parkinsonism at age 47, including 
resting tremor, stooped posture and shuffling gait, but no sensory impairments. He was 
treated with carbidopa/levodopa therapy and responded well. At the age of 56, he 
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developed visual and auditory hallucinations that only partly improved following 
withdrawl of levodopa therapy. His neurological condition gradually deteriorated with 
the emergence of apathy, delusions, confusion, memory impairments and severe 
depression.   He died at the age of 81.  
Postmortem examination revealed extensive loss of pigmented neurons in the SNpc and 
LC without neuronal loss in other brain regions. Numerous LBs, LNs and α-synuclein 
immunoreactive spheroids were found in the SNpc (Fig. 2-2F). α-Synuclein inclusions 
were frequent in the amygdala and in the hippocampal formation (Fig. 2-2G) and sparse 
in the neocortex.  NFTs were abundant in the hippocampal formation (Fig. 2-2H, I) and 
the amygdala. Tau-containing inclusions were rare in other brain regions. SPs were 
infrequent in all regions of the brain. No inclusions were detected with antibodies specific 
to LRRK2. The clinical and pathological features of this patient are consistent with a 
primary diagnosis of PD and a secondary diagnosis of tangle predominant senile 
dementia.  
Phosphorylation of S129 in α-Synuclein in the Pathological Inclusions of Patients 
with LRRK2 Mutations   
Since the multiple functional domains and in-vitro kinase activity of LRRK2 has made 
LRRK2 a prime candidate for regulating signal transductions pathways, and α-synuclein 
is phosphorylated at S129 in pathological inclusions,(95) we therefore analyzed the 
phosphorylation state of α-synuclein in patients with LRRK2 mutations. Using an anti-
phospho-S129 α-synuclein specific antibody (pSyn 129a), the vast majority of α-
synuclein pathological inclusions in the brains of both patients D and E were immuno-
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positive for phosphorylated Ser129 α-synuclein (Fig. 2-3). Similar phosphorylation of α-
synuclein was also observed in 2 other previously described patients (105) carrying the 
G2019S mutation (data not shown). 
 
Figure 2-3. Double-labeling Immunofluorescence Analysis of α-Synuclein Phosphorylated at S129 in 
Pathological Inclusions of Patients with LRRK2 Mutations. Double-labeling immunofluorescence 
analysis demonstrating the presence of α-synuclein phosphorylated at S129 in the vast majority of α-
synuclein inclusions in patients with LRRK2 mutations. Depicted are tissue sections from the SNpc from 
patient D (A-C) and the amygdala from patient E (D-F). Panels A and D show immunostaining with the 
rabbit anti-α-synuclein antibody SNL-4 (green) and panels B and E depicts staining with mouse anti-
phospho-S129 α-synuclein antibody pSyn 129a (red). The overlays are shown in C and F. Scale bar = 
65µm. 
TDP-43 Cytoplasmic Inclusions in Patients with LRRK2 Mutations 
“Tau-negative, α-synuclein negative, ubiquitin-only” positive inclusions have been 
reported in some patients with LRRK2 mutations (347, 355).  Recently, a patient with 
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frontotemporal lobar degeneration with ubiquitinated neuronal inclusions has been 
reported to carry the G2019S mutation (62). Since TDP-43 has recently been identified as 
a major component of ubiquitin inclusions in frontotemporal lobar degeneration (241) 
and a subset of PD patients have TDP-43-containing inclusions (239), the presence of 
TDP-43-positive inclusions in patients with LRRK2 mutations was ascertained. 
Occasional cytoplasmic TDP-43 inclusions were observed in both patient D and E, but 
only in the temporal cortex (Fig. 2-4). No similar cytoplasmic TDP-43 inclusions were 
observed in the brains of the three previously reported PD patients carrying the G2019S 
LRRK2 mutation (105), or an additional five sporadic PD patients analyzed (data not 
shown). 
 
Figure 2-4. TDP-43 Cytoplasmic Inclusions in Patients with LRRK2 Mutations. Staining with an 
antibody to TDP43 revealed the presence of TDP-43 cytoplasmic inclusions in the temporal cortex of 
patient D (A) and patient E (B, C). Aberrant cytoplasmic TDP-43 inclusions are depicted by arrows, and 
normal nuclear localization is indicated by arrowheads. Scale bar = 25µm. 
DISCUSSION   
The identification and characterization of patients with mutations in LRRK2 is pivotal in 
understanding the effects of aberrations of the various domains of this protein.  Herein, 
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we describe the clinical and pathological findings of two patients with missense 
substitutions in LRRK2 identified from a cohort of patients with pathologically confirmed 
PD and DLB.  One subject (patient D) was found to harbor the R793M amino acid 
substitution and presented with the typical clinical and pathological features of PD. This 
variant has been previously reported in three patients with PD (2 familial and 1 sporadic), 
one patient with primary progressive aphasia, and four 40-61 year old control individuals 
(4 out of a total of 2065, 0.2%) (19, 43, 88, 320).  The presence in a small percentage of 
unaffected individuals contests the pathogenicity of the R793M substitution; however, 
since these individuals are still relatively young (40-61 year old) it possible that they may 
yet manifest disease with age. Like the G2019S mutation (124, 166, 199), the R793M 
substitution may be associated with reduced, age-dependent penetrance, or it may confer 
increased risk for expression of clinical disease, similar to the G2385R mutation (75, 
309). The nature of the R793M substitution, a disruption of two highly conserved basic 
residues within a stretch of hydrophobic residues (Fig. 2-1D), further suggests potential 
pathogenic properties. Irrespective of the pathogenicity or risk association, this is the first 
pathological characterization of a patient with the R793M variant. This patient 
demonstrated the classical clinical and pathological features of PD. 
The second patient (patient E) was found to have a novel mutation L1165P in LRRK2. 
This patient presented with onset in middle age and had a long duration of illness (34 
years). Although this patient had typical features of PD, he also became severely 
demented. The abundance of tau pathology in the hippocampal formation without SPs 
and concurrent dementia is consistent with a secondary diagnosis of tangle predominant 
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senile dementia (also termed senile dementia with tangles).  The relatively early onset of 
illness in this patient and the lack of this substitution in more than 366 control patients 
suggest that this mutation may be pathogenic. In addition, L1165 is highly conserved 
across multiple species (Fig. 2-1C) and the L to P substitution would be predicted to 
cause a dramatic structural change within the Leucine-rich domain. However, since the 
function of this region in LRRK2 is unknown, the overall effect of this mutation is 
unclear, and it is uncertain if the atypical pathological features of this patient are directly 
associated with this amino acid substitution.  Although, it is notable that severe 
neuropsychiatric symptoms also have been described in a subset of patients with the 
G2019S and I2020T mutations (123, 321). 
Most patients with mutations in LRRK2 present with clinical PD and have typical LB 
pathology, but a subset of patients have diverse pathological findings. These differences 
cannot solely be explained by the nature of specific mutations since significant 
differences can be observed between patients with the same mutation. For example, while 
17 of the 20 autopsied PD patients reported with the G2019S mutation have shown 
classical nigral degeneration with nigral LBs (105, 111, 254, 276), three cases have 
presented pathological findings indicating concurrent Alzheimer disease (105, 276).  Two 
patients were shown to have nigral degeneration without Lewy pathology (99, 105), and 
the third lacked Lewy pathology but presented with a tauopathy with features suggestive 
of supranuclear palsy and early Alzheimer disease-type pathology (269).  
Atypical clinical features associated with LRRK2 mutation were first observed in the 
Canadian family A with the Y1699C mutation where amyotrophy was observed in 
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addition to Parkinsonism in some patients (355). The autopsies of two individuals from 
this kindred demonstrate SN degeneration, a paucity of α-synuclein positive LB and LN 
pathology, and the presence of “ubiquitin-positive” cytoplasmic and nuclear inclusions. 
On the other hand, individuals from the Lincolnshire kindred that carry the same 
mutation had clinical PD and LB brain pathology (172).  Diverse pathological findings 
have also been reported for the R1441C mutations carried within the Canadian family D.  
Autopsies of two of the documented cases present classical α-synuclein positive LB and 
LN pathology, but the third has tau pathology reminiscent of progressive supranuclear 
palsy.  The fourth patient lacked Lewy pathology; however nonspecific loss of 
dopaminergic neurons with ubiquitin-positive inclusions were found (347, 355).  
Although α-synuclein inclusions are more frequently observed in patients with LRRK2 
mutations than aggregates comprised of other proteins, all types of proteinaceous 
inclusions may contribute to neuronal dysfunction.  TDP-43 has been identified as a 
major component within ubiquinated neuronal intranuclear inclusions of patients with 
frontotemporal lobar degeneration (241). Recently, the G2019S mutation was identified 
in an individual with frontotemporal lobar degeneration with ubiquinated neuronal 
intranuclear inclusions (62), and these inclusions have recently been found to be 
comprised of TDP-43 (241). Within the current study, histological analysis revealed 
occasional cytoplasmic TDP-43 inclusions within the temporal cortex of patients D and 
E.  This is the first report of a histological analysis for TDP-43-positive inclusions in 
patients harboring LRRK2 variants.  It would be interesting to determine whether the 
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“ubiquitin-only” inclusions that have been previously reported in some patients with the 
Y1699C and R1441C mutations are comprised of TDP-43.  
It can be surmised from the wide range of disease onset, incomplete penetrance, and 
diverse pathological findings associated with LRRK2 mutations that these alterations may 
render neurons more vulnerable to other insults that can result in neuronal degeneration 
with or without protein aggregation. Further studies will be required to better understand 
the mechanisms of neurodegeneration associated with LRRK2 mutations and the 
contribution of protein aggregation. 
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CHAPTER THREE 
 
IDENTIFICATION OF COMPOUNDS THAT INHIBIT THE KINASE 
ACTIVITY OF LEUCINE-RICH REPEAT KINASE 2 
 
 
 
 
 
Data from this chapter was published in: 
Covy JP, Giasson BI (2009).  Identification of compounds that inhibit the kinase activity 
of leucine-rich repeat kinase 2.  Biochem Biophys Res Commun. 378; 473-7 
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ABSTRACT 
Mutations in leucine-repeat rich kinase-2 (LRRK2) are the most common known cause of 
late-onset Parkinson’s disease. In this study, a novel system to purify LRRK2 was used to 
characterize the specificity of this kinase and identify small compounds that can inhibit 
kinase activity.  The specificity of this enzyme for the phosphorylation of T558 site in 
moesin was established by using a spectrum of synthetic peptides with well-characterized 
kinase recognition motifs.  The G2019S mutation, which is the most common disease 
causing alteration in LRRK2, markedly increased the activity (~10 fold).  A screen for 
molecular inhibitors identified several compounds (Gö6976, K252a and staurosporine) 
that share a basic indolocarbazole structure as potent inhibitors. The identification of 
these compounds will be important tools to study the biological function of LRRK2 in 
vivo, and can be used as starting points to generate more selective inhibitors that could 
have therapeutic application in Parkinson’s disease.   
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INTRODUCTION 
Parkinson’s disease is the most common neurodegenerative movement disorder.  The 
principal pathologies of PD are the loss of dopaminergic neurons in the SNpc in addition 
to the presence of intracytoplasmic inclusions known as LBs and LNs in some of the 
remaining dopaminergic neurons (92, 119). The mechanism(s) and cellular insults 
leading to the demise of neurons in PD are under investigation; however oxidative stress, 
protein misfolding, and mitochondrial dysfunction have been implicated as factors in the 
disease process (48, 65, 271).   
The discovery of specific genes that can be causal of PD has provided important new 
insights into the cellular pathways that are involved in the pathobiology of PD (29, 174, 
263, 329).   Studies in the past few years have revealed that autosomal dominant 
missense mutations in the LRRK2 gene (also known as PARK8) are collectively the 
single most commonly known cause of late-onset PD (250, 355).  In particular, the 
G2019S mutation is the most prevalent, and is responsible for 2–8% of hereditary PD, 
and 1-2% of sporadic PD cases (69, 73, 110, 111, 166, 245, 251).  In North African Arabs 
and Ashkenazi Jews, the G2019S has been reported to be causal of 20-40% of PD cases 
(198, 199, 248). 
LRRK2 is a large 2527 amino acid protein with several discrete domains that include 
many leucine-rich repeats, a Ras (renin-angiotensin system) of complex (ROC) domain, 
which belongs to the Ras GTPase superfamily, and a kinase domain towards the C-
terminal end (110, 250, 355). In vitro, LRRK2 functions as a S/T kinase that can undergo 
autophosphorylation, and can phosphorylate the generic kinase substrate myelin basic 
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protein (MBP) (160, 342, 343). It was recently shown that T688 in moesin can be 
phosphorylated by LRRK2 (160). The G2019S mutation appears to affect the activation 
loop of the kinase domain and in some in vitro studies it results in 2-3 fold increase in 
kinase activity (160, 342) which may lead to neurotoxicity (131, 296, 343). Nevertheless, 
there is still limited information on the specificity of LRRK2, and inhibitors for this 
kinase have not been reported. In this study we describe a novel system to purify active 
recombinant LRRK2. This recombinant enzyme was used to characterize the specificity 
of LRRK2 and identify small compounds that can inhibit the kinase activity. Our findings 
show that LRRK2 kinase activity is inhibited by several inhibitors that share a basic 
indolocarbazole structure.   
MATERIALS AND METHODS 
Materials 
Goat anti-glutathione-S-transferase (GST) polyclonal antibody was purchased from 
Amersham Biosciences (Piscataway, NJ). 1182 is a rabbit polyclonal antibody raised 
against a recombinant His-tagged LRRK2 protein fragment corresponding to amino acid 
residues 841-960.The shuttling vector pCR8/GW/TOPO and the mammalian expression 
GST-tagged vector pDEST27 were purchased from Invitrogen (Carlsbad, CA).  Bovine 
MBP and the synthetic peptides Kemptide (LRRASLG), caesin kinase 2 substrate 
(RRRADDSD), MBP fragment 104-118 (GKGRGLSLSRFSWGA), and [Ser25]-PKC 
fragment 19-31 (RFARKGSLRQKNV) were purchased from Sigma-Aldrich (St. Louis, 
MO). The synthetic peptides MBP fragment 4-14 (KRPSQRSKYL), MBP fragment 94-
102 (APRTPGGRR), MARCKS-derived peptide (KKRFSFKKSFKL), and PKC-delta 
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peptide substrate (RFAVRDMRQTVAVGVIKAVDKK) were purchased from 
Calbiochem/EMD Biosciences (Gibbstown, NJ). LRRKtide (RLGRDKYKTLRQIRQ) 
was synthesized and purified on reverse phase HPLC by the W.M Keck Biotechnology 
Resource Center at Yale University, New Haven, CT. The following kinase inhibitors 
were purchased from Calbiochem/EMD Biosciences: IC261, 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole (DRB), Gö6976, H89, K-252a, K-252b, kenpaullone, KN-
62, LY294002, ML-7, olomoucine, PD98059, Raf1 kinase inhibitor I, rapamycin, 
roscovitine, SB203580, staurosporine, U0126, wortmannin, Y-27632. 
Cell Culture 
Human embryonic kidney 293T cells (293T) were cultured in Dulbecco's modified 
medium (DMEM) high glucose (4.5gm/L) supplemented with 10 % fetal bovine serum 
(FBS), 100U/ml penicillin, 100U/ml streptomycin, and 2mM L-glutamine. 
LRRK2 Expression Constructs 
The full-length human LRRK2 cDNA was amplified by PCR using Taq polymerase 
AccuPrime SuperMix (Invitrogen) and cloned by topoisomerase reaction into the 
shuttling vector pCR8/GW/TOPO. To generate the cDNA encoding the G2019S 
mutation, the LRRK2 cDNA fragment spanning the AvrII and NcoI restriction sites in 
LRRK2 was amplified by PCR and cloned by topoisomerase reaction into the vector 
pCR4-TOPO (Invitrogen). The mutation corresponding to the G2019S amino acid 
substitution was generated using the QuickChange® Site Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). A LRRK2 AvrII/NcoI cDNA fragment containing the LRRK2 
“triple kinase-dead” (TKD) mutant (131) was amplified by PCR using a plasmid kindly 
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provided by Dr. Mark Cookson and cloned in the vector pCR4-TOPO. In this TKD 
mutant, the amino acid responsible for ATP binding (K1906A), the active site aspartate 
(D1994A), and the Mg2+ binding site (D2017A) ware mutated. The AvrII/NcoI DNA 
fragments containing either the G2019S or TKD mutant were reintroduced into full-
length LRRK2 by subcloning with these restriction enzymes. The sequence of the 
plasmids was verified by DNA sequencing using primers that span the whole cDNA as a 
service offered by the DNA Sequencing Facility of the University of Pennsylvania. 
WT and mutants full-length LRRK2 cDNAs were introduced into the pDEST27 vector 
by recombinase reaction using LR Clonase II enzyme (Invitrogen) to generate a plasmid 
expressing N-terminal GST-tagged protein. 
Western Blotting Analysis 
Proteins were resolved on SDS-polyacrylamide gels by SDS-PAGE and 
electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories, 
Hercules, Ca) in buffer containing 190 mM glycine, 25 mM Tris-base and 10 % 
methanol. Membranes were blocked with a 5% powdered skimmed milk solution 
dissolved in Tris buffered saline (50 mM Tris, pH 7.6, 150 mM NaCl), incubated with 
primary antibody followed with an anti-goat antibody conjugated to horse radish 
peroxidase, developed with Western Lightning Chemiluminescence Reagents 
(PerkinElmer Life Sciences (Boston, MA) and exposed onto X-Omat Blue XB-1 films 
(Kodak, Rochester, NY). 
In-Vitro LRRK2 Kinase assays 
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293T cells were transiently transfected with pDEST27/LRRK2 expression plasmid using 
calcium phosphate precipitation method buffered with N, N-bis (2-hydroxyethyl)-2-
amino-ethanesulfonic acid (BES) (42). 48-72 hours after transfection, cells were washed 
and harvested with PBS, and resuspended in lysis buffer (25nM Tris pH 7.4, 5nM EDTA, 
10mM beta-glycerol phosphate, 1mM NaVO4, 1% Triton X-100, 0.5% glycerol with 
protease inhibitor cocktail) at 4ºC. Cell debris were removed by sedimentation at 
13,000xg for 15 min, and supernatants were precleared by incubation with sepharose 
beads that were removed by sedimentation. Supernatants were incubated with 
glutathione-sepharose beads (GE Healthcare) for 3 hrs at 4ºC. Beads were extensively 
washed with lysis buffer (5 times) and wash buffer (25mM Hepes, pH. 7.4, 1mM DTT, 
10 mM β-glycerophosphate)(5 times) and eluted with wash buffer with 20mM 
glutathione. Kinase reactions were conducted at 25oC by incubating purified GST-
LRRK2 in 25µL of kinase buffer (25mM Hepes, pH. 7.4, 1mM DTT, 10mM β-
glycerophosphate, 10mM MnCl2, 1µM ATP, 5µCi [γ-32P]ATP) with 0.04 mg/ml MBP or 
0.04 mg/ml synthetic peptide. For autophosphorylation or phosphorylation of MBP, 
reactions were stopped with the addition of sodium dodecyl sulfate (SDS) sample buffer 
and heating to 100°C for 5 min. Samples were resolved onto 6% or 15% SDS-
polyacrylamide gels, stained with Commassie R-250 staining solution (0.5% Coomassie 
R-250, 25% isopropanol, 10% acetic acid), destained with 50% methanol/5% glycerol, 
dried and exposed to a PhosphorImager plate (Molecular Dynamics, Piscataway, NJ), and 
visualized using ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). For 
the analysis of the phosphorylation of peptides, peptides were applied to individual 
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2.5cm-diameter disks of P-81 phosphocellulose filter paper (Schleicher & Schuell) that 
were immediately immersed in 75mM phosphoric acid. After extensive wash with 75mM 
phosphoric acid, P-81 filters were rinsed with acetone and allowed to air dry. Filters were 
immersed in Cytoscint liquid scintillation cocktail (Fisher Scientific) and 32P radioactivity 
on each filter was measured by liquid scintillation using an LS6500 counter (Beckman 
Coulter). 
RESULTS AND DISCUSSION 
Generation and Characterization of Active Full-Length GST-LRRK2. 
In order to readily generate substantial amounts of purified LRRK2, the full-length 
enzyme was expressed in 293T cells as an N-terminal tagged GST protein that was 
purified using glutathione-sepharose beads as described in “Materials and Methods” (Fig. 
3-1A).  Since the G2019S mutation is the most common alteration causal of PD and 
several studies have demonstrated increased kinase activity due to this mutation, the 
enzyme with this mutation was also produced. To verify the specificity of each enzyme, 
the “TKD” kinase dead version of this protein (131) also was assayed.  The in-vitro 
kinase activity of recombinant WT and G2019S GST-LRRK2 was investigated by auto-
phosphorylation and phosphorylation of the generic kinase substrate MBP (Fig. 3-1A).  
The G2019S mutation resulted in a 3-5 fold increase in levels of autophosphorylation as 
well as MBP phosphorylation. The TKD protein demonstrated a paucity of kinase 
activity. To further confirm the specificity of this activity, it was assessed with the 
synthetic peptide LRRKtide, which contains residue T688 in moesin that was previously 
identified as a good substrate for LRRK2 (160).  Recombinant WT GST-LRRK2 readily 
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phosphorylated LRRKtide, while the dead mutant showed no activity. In contrast, the 
activity for the G2019S mutant was ~10 times higher than for WT in this assay (Fig 3-
1B), suggesting that the effects of the G2019S mutation may be more pronounced than 
previously believed. The reason(s) for the greater increase in kinase activity by the 
G2019S mutation using LRRKtide in this system are currently under investigation.   
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Figure 3-1. Characterization of 
recombinant GST-LRRK2 activity. (A) 
Western blot analysis with anti-GST or 
anti-LRRK2 (1182) antibody showing 
glutathione affinity chromatography 
purified WT, G2019S and TKD GST-
LRRK2 compared to mock transfection. 
Autoradiography showing that WT and 
G2019S GST-LRRK2 undergo 
autophosphorylation and that they 
phosphorylate MBP, while the TKD mutant 
is deficient in activity, similar to mock 
transfection. (B-D) Substrate peptide 
analysis showing that WT and G2019S 
GST-LRRK2 specifically phosphorylate 
LRRKtide, but not a spectrum of other 
kinase peptide substrates. 
 
 
To further characterize the in-vitro kinase activity of LRRK2, and screen for other motifs 
that this enzyme may recognize, the ability of GST-LRRK2 to phosphorylate 
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characterized synthetic peptides with known kinase recognition motifs was analyzed. 
Some of the peptides studied were based on the ability of LRRK2 to phosphorylate MBP 
as well as the findings from the inhibitor studies (see below). GST-LRRK2 was assayed 
for the ability to phosphorylate PKC substrates (MBP fragment 104-118, [Ser25]-PKC 
fragment 19-31, MBP fragment 4-14, MARCKS PSD-Derived peptide), ERK1/2 
substrate (MBP fragment 94-102), PKA  substrate (Kemptide), and casein kinase II 
specific peptide (Figs. 3-1C and D).  Compared to reactions using LRRKtide, these 
peptides demonstrated less than 5% of the level of phosphorylation indicating that they 
are not substrates for LRRK2 (Fig. 3-1C). Similarly, none of these peptides were 
substrates for G2019S GST-LRRK2 (Fig. 3-1D). 
Recombinant GST-LRRK2 was used to Screen a Range of Defined Kinase 
Inhibitors. 
Compounds (listed in “Material and Methods”) specific for different families of kinases 
including protein kinase A, protein kinase C, mitogen-activated protein kinase, mitogen-
activated protein kinase kinase, casein kinase I/II, Ca2+/calmodulin-dependent kinase II, 
glycogen synthase kinase-3, Rho kinase, Raf kinase, myosin light chain kinase, cyclin-
dependent kinases and mixed lineage kinases were assayed using a 1-10uM range.  The 
majority of compounds had no significant affect on kinase activity (data not shown); 
however five inhibitors that abolished kinase activity were identified, and were further 
characterized (Fig 3-2).  Two of these inhibitors inhibited LRRK2 in the high nM range: 
Raf-1 kinase inhibitor I (IC50 ~500nM) (Fig 2D) and Gö6976 (IC50 ~250nM) (Fig 3-
2A).  Three other inhibitors were much more potent, inhibiting LRRK2 in the low nM 
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range: staurosporine (IC50 ~1nM) (Fig 2E), K252a (IC50 ~25nM) (Fig 3-2B), and 
K252b (IC50 ~50nM) (Fig 3-2C).  Similarly, all these inhibitors demonstrated the ability 
to inhibit G2019S LRRK2 (Fig 3-2F). 
 
Figure 3-2. Analysis of GST-LRRK2 kinase activity in the presence of various inhibitors. (A) Gö6976, 
(B) K-252a, (C) K252-b, (D) Raf-1 kinase inhibitor 1 and (E) Staurosporine are shown to be potent 
inhibitors of WT GST-LRRK2 using a range of concentration that was used to approximate the IC50. (F) 
G2019S GST-LRRK2 was also efficiently inhibited by these kinase inhibitors. The values correspond to 
the phosphorylation of LRRKtide in the presence of each inhibitor relative to reactions without inhibitors 
expressed as percent activity.  (n=3, Error bars indicate standard error) 
The four most potent inhibitors of LRRK2 identified here (Gö6976, K252a, K252b and 
staurosporine) all have a basic indolocarbazole structure: a symmetric fusion of 
alternating three benzene and two pyrrole rings with a pyrrolidione ring fused to the 
central benzene structure (135, 274). These molecules are competitive inhibitors 
interacting with the ATP binding site of kinases (86, 169, 171).  Although staurosporine 
is a potent kinase inhibitor, it is not very specific (86, 169).   K252a and K252b were 
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identified from the culture broth of the Nocardiopsis bacterium, and although they were 
initially shown to inhibit PKC (171), they also have been shown to inhibit several other 
kinases (147, 339). Gö6976 was developed as a specific inhibitor of some PKC isozymes 
(223), but more recently it was shown to also inhibit several other kinases (15). The 
identification of kinases inhibitors that are completely specific has been a challenge, but 
once a specific basis structure has been identified several approaches can be used to 
rationally modify kinase inhibitors to make them more selective ligands (35, 57, 193, 
339).  
The identification of potent LRRK2 kinase inhibitors will serve as useful tools for in vivo 
findings where LRRK2 is overexpressed to characterize its biological function. More 
importantly, these compounds can be used as the starting points to generate more 
selective inhibitors that could have therapeutic application given that elevated LRRK2 
activity is a likely cause of pathogenesis in patients with LRRK2 mutations. 
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CHATPER FOUR 
 
THE PATHOGENIC G2019S MUTATION DISRUPTS SENSITIVITY 
OF LEUCINE-RICH REPEAT KINASE 2 TO MANGANESE KINASE 
INHIBITION 
 
 
 
 
 
Data from this chapter was published in: 
Covy JP, Giasson BI (2010).  The pathogenic G2019S mutation disrupts sensitivity of 
leucine-rich repeat kinase 2 to manganese kinase inhibition.  J Neurochem. (In Press) 
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ABSTRACT 
Mutations in leucine-repeat rich kinase-2 (LRRK2) are the most common cause of late-
onset Parkinson disease. Previously, we showed that the G2019S pathogenic mutation 
can cause a dramatic increase (~10 fold) in kinase activity, far above other published 
studies. A notable experimental difference was the use of Mn-ATP as a substrate. 
Therefore, the effects of metal cation-ATP cofactors on LRRK2 kinase activity were 
investigated. It is shown, using several divalent metal cations, that only Mg2+ or Mn2+ can 
support LRRK2 kinase activity. However, for wild-type, I2020T and R1441C LRRK2, 
Mn2+ was significantly less effective at supporting kinase activity. In sharp contrast, both 
Mn2+and Mg2+ were effective at supporting the activity of G2019S LRRK2. These 
divergent effects associated with divalent cation usage and the G2019S mutation were 
predominantly due to differences in catalytic rates. However, LRRK2 was shown to have 
much lower (~40 fold) ATP Km for Mn-ATP compared to Mg-ATP.  Consequently, sub-
stoichiometric concentrations of Mn2+ can act to inhibit the kinase activity of wild-type, 
but not G2019S LRRK2 in the presence of Mg2+. From these findings, a new model is 
proposed for a possible function of LRRK2 and the consequence of the G2019S LRRK2 
pathogenic mutation. 
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INTRODUCTION 
Parkinson disease is the second most prevalent neurodegenerative disease in the 
developing world, and is believed to result from complex genetic and environmental 
factors. It is characterized clinically by resting tremor, bradykinesia, postural instability, 
and muscle rigidity (152, 292).  Although primarily viewed as an idiopathic disease, a 
number of gene defects have been established to either cause or increase the risk of PD 
[reviewed in (23, 28, 92, 143, 275, 318)]. More specifically, autosomal dominant 
missense mutations in the gene for LRRK2 (PARK8) are the most common known cause 
of PD (110, 250, 355). At least 5 LRRK2 missense mutations are considered definitely 
pathogenic, but many other amino acid substitutions within this protein have been linked 
to PD (see Fig. 1A) (26, 110, 224, 250, 314, 355). The most prevalent mutation, G2019S, 
is reportedly responsible for 0.6-1.6% of sporadic PD (69, 111, 166) and 2-8% of familial 
PD cases (69, 73, 145, 166, 245, 251). In certain ethnicities, such as North African Arabs 
and Ashkenazi Jews, the G2019S mutation is even a greater factor contributing to PD 
(22-41% of individuals with disease) (198, 199, 248). 
LRRK2 is a widely-expressed 2527 amino acid protein with several discrete domains 
(Fig. 4-1A) (250, 343, 355). Containing a Ras-of-complex (ROC)/GTPase domain 
followed by a C-terminal of RAS (COR) domain, it is a member of the ROCO protein 
family (see Fig. 4-1A). The LRRK2 kinase domain displays highest sequence homology 
to the mixed-linage kinase subfamily of mitogen-activated protein kinase kinase kinases, 
so named due to kinase sub-domain structures resembling both protein Y- and S/T-
kinases (218, 342, 343). To date it has been shown that LRRK2 can function as a S/T-
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kinase that can undergo autophosphorylation (7, 53, 134, 160, 213, 296, 342, 343); 
although its ability to function as a Y-kinase has not been rigorously investigated. Some 
modeling studies have suggested that LRRK2 may be a dual specificity kinase, 
phosphorylating both S/T and Y residues (218, 343), but so far it has been shown to 
function predominantly as a S/T-kinase (7, 343) and only weak activity towards the Y-
kinase substrate poly(E)tyrosine was reported (342).  Furthermore, the biological 
functions and regulation of LRRK2, and the effects of disease-causing mutations therein 
are still ill-defined(130). For example, the R1441C mutation was demonstrated to 
increase kinase activity in some studies(342, 343), but others have reported no significant 
change (7, 118, 160). The I2020T mutation was documented to either modestly increase 
(117, 118), show no change (7) or decrease kinase activity (160). Most studies of the 
G2019S mutation demonstrated increased kinase activity, although modest (2-3 fold) (7, 
118, 131, 160, 342, 343). Recently, we have shown that in one experimental paradigm, 
the G2019S LRRK2 mutant can demonstrate 10-fold greater kinase activity than wild-
type (WT) LRRK2 (53). One notable difference is that we used Mn2+ as an ATP cofactor, 
while most other published studies have used Mg2+. Therefore, in this study we assessed 
the relative kinetic effects of Mg2+ versus Mn2+ on the catalytic properties of WT LRRK2 
and some disease-causing mutants thereof.  
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Figure 4-1. Characterization of recombinant LRRK2 kinase activity. (A) Schematic of LRRK2 
showing the major domains [ankyrin-like (ANK), Leucine-rich repeat (LRR), Ras-in-complex (ROC), C-
terminal of RAS (COR)] and the position of the mutations that are considered definitely pathogenic. (B) 
Western blot with anti-GST antibody showing equal amounts of glutathione affinity-purified recombinant 
WT and mutant (G2019S, I2020T and R1441C) GST-LRRK2 full-length proteins. (C) Relative kinase 
activity of WT, R1441C, G2019S, and I2020T LRRK2 using 200µM ATP, 400µM LRRKtide and several 
individual divalent cations (Mg2+, Mn2+, Cd2+, Ca2+, Ni2+, Zn2+) at 5mM. The data was standardized so that 
the phosphorylation reaction of LRRKtide with Mg2+ for each LRRK2 variant was normalized to 100%.  
(D) Comparative assessment of the ability of WT and G2019S LRRK2 to phosphorylate LRRKtide, 
LRRKtide-TA or LRRKtide-YF (300µM each) in the presence of 200µM ATP and either 5mM Mg2+ or 
Mn2+.  (E) Assay demonstrating that the time-course of LRRK2 kinase activity was linear over 120 min 
using 200µM ATP, 400µM LRRKtide and either 5mM Mg2+ or Mn2+. For each LRRK2 variant, the activity 
was standardized as 100% for kinase reactions in 5mM Mg2+ at 60 minutes. The error bars represent 
standard error of the mean. 
MATERIALS AND METHODS 
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Materials 
Goat anti-GST polyclonal antibody was purchased from Amersham Biosciences 
(Piscataway, NJ). The shuttling vector pCR8/GW/TOPO and the mammalian expression 
GST-tagged vector pDEST27 were purchased from Invitrogen (Carlsbad, CA).  
LRRKtide (RLGRDKYKTLRQIRQ), LRRKtide-TA (RLGRDKYKALRQIRQ) that is 
deficient in S/T residues, LRRKtide-YF (RLGRDKFKTLRQIRQ) that is deficient in Y 
residues, and Nictide (RLGWWRFYTLRRARQGNTKQR) were synthesized and 
purified on reverse phase HPLC by GenScript USA Inc. (Piscataway, NJ). The synthetic 
peptides MBP fragment 104-118 (GKGRGLSLSRFSWGA), Kemptide (LRRASLG), and 
caesin kinase 2 substrate (RRRADDSD) were purchased from Sigma-Aldrich (St. Louis, 
MO). The synthetic peptides MBP fragment 4-14 (KRPSQRSKYL), MBP fragment 94-
102 (APRTPGGRR), MARCKS PSD-derived peptide (KKRFSFKKSFKL), and PKCδ 
peptide substrate (RFAVRDMRQTVAVGVIKAVDKK) were obtained from 
Calbiochem/EMD Biosciences (Gibbstown, NJ). Kinase inhibitors JAK3 VI, K252-A, 
PKR, ROCK-IV, and staurosporine were purchased from Calbiochem/EMD Biosciences, 
and sunitinib was purchased from Sigma-Aldrich. 
Cell Culture 
Human embryonic kidney 293T cells were cultured in Dulbecco's modified medium with 
high glucose (4.5gm/L) supplemented with 10% fetal bovine serum, 100U/ml penicillin, 
100U/ml streptomycin, and 2mM L-glutamine. 
LRRK2 Expression Constructs 
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The full-length human LRRK2 cDNA was amplified by PCR using Taq polymerase 
AccuPrime SuperMix (Invitrogen) and cloned by topoisomerase reaction into the 
shuttling vector pCR8/GW/TOPO. To generate the cDNAs encoding the G2019S or 
I2020T mutations, the LRRK2 cDNA fragment spanning the AvrII and NcoI restriction 
sites in LRRK2 was amplified by PCR and cloned by topoisomerase reaction into the 
vector pCR4-TOPO (Invitrogen). To generate the cDNA encoding the R1441C mutation, 
the LRRK2 cDNA fragment spanning the NdeI and SpeI restriction sites in LRRK2 was 
amplified by PCR and cloned by topoisomerase reaction into the vector pCR4-TOPO 
(Invitrogen). The mutations corresponding to the R1441C, G2019S or I2020T amino acid 
substitutions, respectively, were generated using the QuickChange® Site Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). The AvrII/NcoI DNA fragments containing 
either the G2019S or I2020T mutants or the NdeI/SpeI DNA fragments containing the 
R1441C mutation were reintroduced into full-length LRRK2 by subcloning with these 
restriction enzymes. The sequence of the plasmids was verified by DNA sequencing 
using primers that span the whole cDNA as a service offered by the DNA Sequencing 
Facility of the University of Pennsylvania. WT and mutant full-length LRRK2 cDNAs 
were introduced into the pDEST27 vector by recombinase reaction using LR Clonase II 
enzyme (Invitrogen) to generate a plasmid expressing N-terminal GST-tagged protein.   
Western Blotting Analysis 
Proteins were resolved on SDS-polyacrylamide gels by SDS-PAGE and 
electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories, 
Hercules, Ca) in buffer containing 190mM glycine, 25mM Tris-base and 10% methanol. 
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Membranes were blocked with a 5% powdered skimmed milk solution dissolved in Tris 
buffered saline (50mM Tris, pH 7.6, 150mM NaCl), incubated with anti-GST antibody 
followed with an anti-goat antibody conjugated to horse radish peroxidase, developed 
with Western Lightning Chemiluminescence Reagents (PerkinElmer Life Sciences 
(Boston, MA) and exposed onto X-Omat Blue XB-1 films (Kodak, Rochester, NY). 
In-Vitro LRRK2 Kinase Assays 
293T cells were transiently transfected with pDEST27/LRRK2 expression plasmid using 
calcium phosphate precipitation method buffered with N, N-bis (2-hydroxyethyl)-2-
amino-ethanesulfonic acid (BES) (42). 48-72 hours after transfection, cells were washed 
and harvested with PBS, and resuspended in lysis buffer (25mM Tris pH 7.4, 150mM 
NaCl, 5mM EDTA, 10mM beta-glycerol phosphate, 1mM NaVO4, 1 % Triton X-100, 
0.5% glycerol with protease inhibitor cocktail) at 4oC. Cell debris were removed by 
sedimentation at 13,000xg for 15 minutes, and supernatants were precleared by 
incubation with sepharose beads that were removed by sedimentation. Supernatants were 
incubated with glutathione-sepharose beads (GE Healthcare) for 3 hours at 4oC. Beads 
were extensively washed with lysis buffer (5 times) and wash buffer (25mM Hepes, pH. 
7.4, 1mM DTT, 10mM β-glycerophosphate) (5 times) and eluted with wash buffer with  
20mM glutathione. The kinase reactions were conducted at 25oC by incubating purified 
GST-LRRK2 in 25µL of kinase buffer (25mM Hepes, pH. 7.4, 10mM β-
glycerophosphate), with the added specified divalent cation, and varying [γ-32P]ATP (4 
Ci/mmoles) (1µM to 800µM) and LRRKtide peptide (1µM to 1200µM) concentrations as 
specified for each experiment. All reactions were conducted for 60 minutes at 25oC, 
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except for the time course experiments that were conducted for the indicated times. 
Reactions were applied to individual 2.5cm-diameter disks of P-81 phosphocellulose 
filter paper (Schleicher & Schuell) that were immediately immersed in 75mM phosphoric 
acid. After extensive wash with 75mM phosphoric acid, P-81 filters were rinsed with 
acetone and allowed to air dry. Filters were immersed in Cytoscint liquid scintillation 
cocktail (Fisher Scientific) and 32P radioactivity on each filter was measured by liquid 
scintillation using an LS6500 counter (Beckman Coulter). A unit of LRRK2 activity was 
defined as the amount of enzyme that catalyzed the incorporation of 1pmol of 32P into 
LRRKtide. Km and Vmax parameters were calculated using Graph-Pad Prism v5.01. 
For autophosphorylation of LRRK2, reactions were stopped with the addition of SDS 
sample buffer and heating to 100°C for 5 min. Samples were resolved onto 6% SDS-
polyacrylamide gels, dehydrated in a 50% Methanol, 10% glycerol, 10% acetic acid 
solution, dried and exposed to a PhosphorImager plate (Molecular Dynamics, 
Piscataway, NJ), and visualized using ImageQuant software (Molecular Dynamics, Inc., 
Sunnyvale, CA). 
RESULTS 
We recently generated a novel system to purify substantial amounts of active 
recombinant full-length LRRK2 expressed in 293T mammalian cells (53). In this system, 
LRRK2 is expressed as an N-terminal tagged GST protein that is purified using 
glutathione-sepharose beads as described in “Materials and Methods”.  The kinase 
activity of this enzyme was previously characterized for specificity using a kinase dead 
version as well as kinase inhibitors in the presence of Mn2+.  The specificity of this 
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activity was further confirmed using a series of previously published and characterized 
LRRK2 kinase inhibitors (7, 244, 273) in the presence of Mg2+ (Fig. 4-2). For the studies 
described here, WT and 3 pathogenic mutants of LRRK2 (R1441C, G2019S, and 
I2020T) were purified to equivalent levels (Fig. 4-1B).   The kinase reactions in the 
present studies were conducted using the synthetic peptide LRRKtide that spans residue 
T558 of moesin, which was previously identified as a robust in vitro substrate for LRRK2 
(7, 34, 53, 160). 
 
Figure 4-2. Analysis of WT and G2019S LRRK2 kinase activity in the presence of various inhibitors. 
Kinase reactions were conducted using 400µM LRRKtide, 100µM ATP, and 5 mM Mg2+. JAK3 VI, K252-
A, PKR, ROCK-IV, stuarosporine, and sunitinib are shown to be potent inhibitors of WT and G2019S 
LRRK2 at a concentration of 1µM. Values correspond to the phosphorylation of LRRKtide in the presence 
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of each inhibitor relative to reactions without inhibitor expressed as percent activity. The error bars 
represent standard error of the mean. 
Protein kinases require the formation of an ATP-divalent metal complex for the 
phosphoryl transfer of the γ-phosphate of ATP to a protein substrate (178).  Typically, 
Mg2+ serves as the essential metal ion for catalysis, however Mn2+ and other divalent 
cations may support nucleotide binding and subsequent use as a cofactor for phosphoryl 
transfer (52, 84, 180, 306, 324). Several divalent metal cations were tested to assess their 
ability to act as an ATP cofactor for WT and pathogenic variants of LRRK2. This 
analysis was conducted for pathological mutations within the active site (G2019S and 
I2020T) as well as a pathological mutation distinct from this site (R1441C).   Of the 
divalent metal cations assessed, Mg2+ demonstrated the greatest ability to support LRRK2 
kinase activity under the reaction conditions used here (200 µM ATP, 400 µM 
LRRKtide) (Fig. 1C). Mn2+ also demonstrated a modest ability to promote LRRK2 kinase 
activity of WT, R1441C and I2020T LRRK2, however this property was greatly 
enhanced for the G2019S LRRK2 mutant. The other divalent cations tested were not able 
to support LRRK2 kinase activity. 
It is well known that many Y-kinases prefer Mn2+ as an ATP cofactor (52, 84, 155, 180, 
306), and for some dual specificity kinases, the presence of Mn2+ versus Mg2+ can cause a 
switch in preferential activity from a protein S/T-kinase to a protein Y-kinase (154, 350) . 
Therefore, it is possible that Mn2+ may support the activity of LRRK2 as a Y-kinase since 
LRRKtide (RLGRDKYKTLRQIRQ) contains both a T and a Y residue. To further 
investigate the type of kinase activities associated with the use of Mg2+ or Mn2+, kinase 
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reactions for WT, R1441C, G2019S, and I2020T LRRK2 were performed in the presence 
of 5 mM Mg2+ or Mn2+ and LRRKtide, LRRKtide deficient in S/T residues (LRRKtide-
TA; RLGRDKYKALRQIRQ) or LRRKtide that is deficient in Y residues (LRRKtide-
YF; RLGRDKFKTLRQIRQ).  Results showed that only LRRKtide with a T residue 
served as a substrate for LRRK2 in the presence of Mg2+ or Mn2+ (Fig. 4-1D).  To further 
confirm that the persistence of kinetic activity of the G2019S mutant in the presence of 
Mn2+ is not a result of altered substrate specificity, a number of other characterized 
synthetic peptides with known kinase recognition motifs, including the engineered 
LRRK2 substrate Nictide (244), were analyzed in the presence of Mg2+ or Mn2+, and no 
differences in substrate recognition were observed (Fig. 4-3).  
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Figure 4-3. Substrate specificity of WT and G2019S LRRK2. WT and G2019S LRRK2 was assayed for 
the ability to phosphorylate PKC substrates (MARCKS PSD-derived peptide, MBP fragment 4-14, MBP 
fragment 104–118, PKCδ peptide substrate), ERK1/2 substrate (MBP fragment 94–102), PKA substrate 
(Kemptide), casein kinase II specific peptide, and known LRRK2 substrates (LRRKtide and Nictide) in the 
presence of either 5mM Mg2+ or Mn2+.  ATP concentration was at 200µM, and substrates were at 300µM 
(except for Nictide which was at 30µM).  The error bars represent standard error of the mean. 
Time course analysis of the kinase activity for WT, R1441C, G2019S, and I2020T 
LRRK2 in the presence of Mg2+ or Mn2+ was performed to determine the consistent 
progress of the phosphoryl transfer over time.  Results showed that the kinase reaction 
was linear over the course of two hours, allowing extrapolation of initial velocity and 
confirming that differences in kinetic activity were not due to changes in kinase stability 
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(Fig. 4-1E).  In addition, similar to our initial screen of divalent cations, WT, R1441C, 
G2019S, and I2020T LRRK2 kinase activity was much greater in the presence of Mg2+ 
compared to Mn2+ for all enzymes except the G2019S mutant. 
To further investigate the effects of Mg2+ and Mn2+ on LRRK2 kinase activity, the ability 
and extent of each ion to support kinase activity was assessed by varying their 
concentrations.  For all variants of LRRK2 assayed against LRRKtide, increasing the 
concentration of Mg2+ resulted in increased kinase activity with maximum activity at 
5mM.  Mn2+ also supported the kinase activity of LRRK2, but maximal activity was 
observed at ~ 0.5mM and all variants demonstrated a similar relative decrease in activity 
at higher concentrations with ~ 2-fold lower activity at 5mM Mn2+ compared to 0.5mM 
Mn2+ (Fig. 4-4). R1441C and I2020T mutants demonstrated Mn2+ concentration activity 
profiles that were similar to WT LRRK2, but G2019S LRRK2 revealed dramatically 
greater activity than the other LRRK2 variants in the presence of Mn2+ and this was 
especially striking in the presence of Mn2+ below or near sub-stoichiometric 
concentrations of ATP.  
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Figure 4-4. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of WT, R1441C, 
G2019S, and I2020T LRRK2 on LRRKtide phosphorylation. Kinase reactions for (A) WT, (B) 
R1441C, (C) G2019S and (D) I2020T LRRK2 were conducted using 200µM ATP, 400µM LRRKtide and 
varying concentrations of Mg2+ or Mn2+ between 0.1mM and 10mM. The error bars represent standard 
error of the mean. 
These effects were replicated using the synthetic substrate Nictide (Fig. 4-5).  Again, 
Mn2+ is capable of driving kinase activity, although not to the extent of Mg2+ for WT, 
R1441C, and I2020T LRRK2.  For G2019S LRRK2, Mn2+ demonstrated the ability to 
drive much greater kinase activity than for the other LRRK2 variants, and in fact, 
G2019S LRRK2 showed greater kinase activity in the presence of  Mn2+  compared to 
Mg2+ (Fig. 4-5). Although the effects of Mg2+ and Mn2+ on WT, R1441C, G2019S and 
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I2020T LRRK2 kinase activity using either LRRKtide or Nictide are consistent, there are 
some relative differences and more detailed kinetic studies of the difference between 
LRRKtide and Nictide are under investigation.   
 
Figure 4-5. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of WT, R1441C, 
G2019S, and I2020T LRRK2 on Nictide phosphorylation. Kinase reactions for (A) WT, (B) R1441C, 
(C) G2019S and (D) I2020T LRRK2 were conducted using 200µM ATP, 30µM Nictide and varying 
concentrations of Mg2+ or Mn2+ between 0.1mM and 10mM. The error bars represent standard error of the 
mean. 
Similar results for divalent cation preference were observed for autophosphorylation of 
LRRK2.  Increasing concentrations of Mg2+ drove robust autophosphorylation of both 
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WT and G2019S LRRK2, and these levels were greatly reduced in the presence of Mn2+ 
for WT, but not G2019S (Fig. 4-6A).  Interestingly, 0.1mM Mn2+ induced higher 
autophosphorylation activity in both WT and G2019S LRRK2 compared to Mg2. This 
selectivity may reflect higher affinity for ATP-Mn (see below), but direct affects of 
divalent cations on LRRK2 autophosphorylation cannot be excluded and this will require 
further detailed analyses.  Nevertheless, consistent with LRRKtide, WT LRRK2 
exhibited lower autophosphorylation activity in 5mM Mn2+ versus 5mM Mg2+, while 
G2019S LRRK2 displayed similar autophosphorylation in the presence of either 5mM 
Mn2+or Mg2+ (Fig. 4-6B).   
Figure 4-6. Concentration dependent affects of 
Mg2+ and Mn2+ on the autophosphorylation 
activity of WT and G2019S LRRK2.  (A) 
Kinase reactions for WT and G2019S were 
conducted using 100 uM ATP and with varying 
concentrations of divalent cation between 0.1 
mM and 10 mM.  Autoradiography shows the 
effects of increased concentration of Mg2+ or 
Mn2+ autophosphorylation activity.  (B) The 
relative activity of WT and G2019S LRRK2 
when using either Mg2+ or Mn2+ as cofactor at 5 
mM.  The error bars represent standard error of 
the mean. 
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To investigate the nature of the differences in the kinetics properties affected by Mg2+ 
versus Mn2+ and the provocative effects of the G2019S LRRK2 pathogenic mutation, the 
Michaelis-Menton parameters were determined for WT, R1441C, I2020T, and G2019S 
LRRK2 using LRRKtide as a substrate. To ensure that the ATP-cation complex was at 
saturating levels, 5mM Mg2+ or Mn2+ was used to remain at a concentration several fold 
above the highest concentration of ATP.  Furthermore, results showed at this 
concentration of Mg2+, maximal LRRK2 activity is obtained.  Kinetic analyses for the Km 
of LRRKtide, while keeping the ATP concentration constant at 200µM, revealed values 
consistent with previous reports utilizing Mg2+ and N-terminally truncated versions 
(LRRK21326-2527 or LRRK2970-2527) of LRRK2 (7, 160, 244).  The affinity for LRRKtide 
was not dramatically affected by the use of Mg2+ and Mn2+, or by mutations in LRRK2; 
although some subtle changes were observed (Fig. 4-7). The apparent Vmax’s measured 
under these conditions revealed that WT, I2020T and R1441C LRRK2 had much greater 
relative catalytic rates (~10 fold) in the present of Mg2+ versus Mn2+.  In regards to each 
respective cation, the R1441C and I2020T mutants resulted in only small changes in 
catalytic rate compared to WT, while the apparent Vmax for G2019S in the presence of 
Mg2+ was ~2.5-fold greater than WT LRRK2.  However the most dramatic effect was the 
relative maintenance of catalytic activity of G2019S LRRK2 in the presence of Mn2+ 
relative to Mg2+.  This effect was unique to the G2019S mutation.  In fact, for G2019S 
LRRK2, the Vmax in the presence of Mn2+ compared to Mg2+ was only ~ 1.5 fold lower, 
in contrast to the ~9 fold lower activity for WT, R1441C, and I2020T LRRK2. 
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Figure 4-7.  Kinetic characteristics of WT and LRRK2 mutations while varying the concentration of 
LRRKtide as a substrate. (Top) Assessment of the kinetic features of (A) WT, (B) R1441C, (C) G2019S 
and (D) I2020T recombinant LRRK2 with ATP at 200µM with either 5mM Mg2+ or 5mM Mn2+. The 
concentration of LRRKtide was varied as indicated on the x-axis. The error bars represent standard error of 
the mean.  (Bottom) The relative apparent Vmax (U/min) and Km (mM) for. The errors represent standard 
deviations. 
Wildtype 208.9 +/- 11.50 242.6 +/- 14.74 2.57 +/- 0.046 0.304 +/- 0.005
R1441C 208.6 +/- 17.30 300.5 +/- 30.55 3.63 +/- 0.102 0.286 +/- 0.009
G2019S 243.8 +/- 19.64 235.8 +/- 13.09 6.80 +/- 0.243 5.222 +/- 0.084
I2020T 251.7 +/- 37.80 255.5 +/- 35.91 3.31 +/- 0.146 0.282 +/- 0.012
Km Vmax
Mn Mg MnMg
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The determination of the apparent Km of ATP while keeping LRRKtide constant at 
400µM revealed that WT LRRK2 and LRRK2 mutants have a significantly lower ATP 
Km in the presence of Mn2+ compared to Mg2+ (Fig. 4-8). This suggests a greater affinity 
for Mn-ATP than Mg-ATP. ATP Km for WT and R1441C had similar properties, while 
I2020T LRRK2 had a relative lower ATP Km in the presence of either Mg2+ or Mn2+, 
respectively. Conversely, G2019S LRRK2 demonstrated relatively higher ATP Km in the 
presence of either Mg2+ or Mn2+, respectively, compared to WT LRRK2. Again, the 
analyses to assess Vmax values showed that WT LRRK2 demonstrated a greater catalytic 
rate in the presence Mg2+ versus Mn2+, however, the most striking finding was the much 
higher Vmax for G2019S LRRK2 in the presence of Mn2+ compared to WT and other 
mutants of LRRK2.  
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  Km  Vmax 
  Mg  Mn  Mg   Mn 
Wildtype 54.53 +/- 4.73  1.40 +/- 0.173  2.08 +/- 0.044  0.189 +/- 0.003 
R1441C 62.97 +/- 4.02  2.61 +/- 0.472  3.06 +/- 0.049  0.238 +/- 0.006 
G2019S 74.08 +/- 7.73  3.93 +/- 0.436  4.68 +/- 0.126  3.315 +/- 0.057 
I2020T 18.13 +/- 2.63  0.95 +/- 0.153  2.67 +/- 0.078  0.179 +/- 0.004 
 
Figure 4-8.  Kinetic characteristics of WT and LRRK2 mutations while varying the concentration of 
ATP as a substrate. (Top) Assessment of the kinetic features of (A) WT, (B) R1441C, (C) G2019S and 
(D) I2020T recombinant LRRK2 at 400µM LRRKtide with either 5mM Mg2+ or 5mM Mn2+. The 
concentration of ATP was varied as indicated on the x-axis. The error bars represent standard error of the 
mean. (Bottom) The relative apparent Vmax (U/min) and Km (mM) for. The errors represent standard 
deviations. 
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Since under physiological conditions, Mn2+ exists at sub-stoichiometric concentrations 
relative to Mg2+, we compared the relative effects of varying sub-stoichiometric 
concentrations of Mn2+ in the presence of a fixed concentration of Mg2+.  For these 
experiments, Mg2+ was maintained at 5mM while the concentration of Mn2+ was varied 
between 0-5mM. Increasing the concentration of Mn2+ resulted in reduced kinase activity 
for WT, R1441C and I2020T LRRK2 (Fig. 4-9A,B,D), consistent with a greater affinity 
for Mn-ATP versus Mg-ATP paired with a reduction in catalytic activity when utilizing 
Mn-ATP. In sharp contrast, increases in the concentration of Mn2+ between 0.1-1mM 
increased the kinase activity of G2019S LRRK2, while only modestly reducing kinase 
activity at 5mM Mn2+ (Fig. 4-9C).  Given that G2019S LRRK2 levels of kinase activity 
in the presence of Mn2+ reaches a maximum at ~1mM and that this activity is similar to 
G2019S LRRK2 in the presence of 5mM Mg2+ (Fig. 4-4C), but that 5mM Mg2+ in the 
presence of 0.1 or 0.5mM Mn2+ results in higher activity, it is possible that Mn2+ may 
additionally modulate kinase activity by acting at a second site. Overall, these results are 
consistent with those reported recently (212) and show that at millimolar concentrations 
of Mg2+, micromolar concentrations of Mn2+ decrease the levels of LRRK2 kinase 
activity, while the G2019S mutation causes a loss of this negative regulation, if not 
reversing the effect and increasing activity.  
97 
 
 
 
Figure 4-9. Analysis of effects of sub-stoichiometric concentrations of Mn2+ on WT and mutant 
LRRK2 kinase activity driven by Mg2+. The activity of (A) WT, (B) R1441C, (C) G2019S and (D) 
I2020T recombinant LRRK2 was assessed in the presence of 200µM ATP, 400µM LRRKtide and 5mM 
Mg2+ with concentrations of Mn2+ varying from 0-5mM. As a reference, reactions with only 5mM Mn2+ are 
also shown. For each LRRK2 variant, the activity was standardized as 100 % activity for kinase reactions 
with only 5mM Mg2+. The error bars represent standard error of the mean. 
DISCUSSION 
In stark contrast to several other published findings (7, 118, 131, 160, 342, 343), we 
recently demonstrated that the G2019S mutation in LRRK2 could result in a much 
greater kinase activity relative to WT LRRK2 (53). A notable difference in our study was 
the use of Mn2+ as an ATP cofactor compared to the use of Mg2+ in other studies. This led 
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us to investigate the ability of divalent metal cations to support the kinase activity of WT 
and several pathogenic mutants of LRRK2. It was shown that only Mg2+ or Mn2+ could be 
used as ATP cofactors to support the kinase activity of LRRK2, and for WT, I2020T and 
R1441C LRRK2, Mg2+ was a much better cofactor at promoting kinase activity.  
Remarkably, both Mn2+and Mg2+ were effective at promoting the activity of G2019S 
LRRK2. Using LRRKtide peptides deficient in either T or Y resides, it was shown that 
WT and mutants of LRRK2 appear to be exclusively S/T-protein kinases, and Mn2+ does 
not change this specificity.  Furthermore, no changes in specificity were observed for a 
number of known generic kinase substrates for WT or G2019S LRRK2 when utilizing 
Mn2+ or Mg2+.  Interestingly, LRRK2 demonstrated greater activity towards the 
LRRKtide-YF peptide compared to LRRKtide, however, this is consistent with a 
previous study mapping the preferred consensus motif of LRRK2 substrates where it has 
been shown that for the P-2 position, an F is favored over a Y residue (244).  
Assessment of Michaelis-Menton parameters showed that the use of Mn2+ versus Mg2+ 
did not dramatically affect LRRKtide Km. Consistent with previous reports using N-
terminally truncated versions of LRRK2 (7, 273), ATP Km for G2019S LRRK2 was 
higher compared to WT LRRK2, while that of I2020T LRRK2 was lower in the presence 
of Mg2+. WT and all mutants of LRRK2 demonstrated significantly lower ATP Km for 
Mn-ATP compared to Mg-ATP, and similar findings have been attributed predominantly 
to a high affinity for Mn-ATP (212). WT, R1441C and I2020T LRRK2 showed slower 
catalytic rates in the presence of Mn2+ compared to Mg2+. A dramatically higher Vmax for 
G2019S in the presence of Mn2+ compared to WT LRRK2 is the predominant reason for 
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the ~10 fold greater level of kinase activity for G2019S LRRK2 versus WT LRRK2 that 
we previously reported (53). Consistent with these data, similar findings were observed in 
a recent study using a truncated version (LRRK2970-2527) of LRRK2 expressed and 
purified from baculovirus-infected insect cells (212). However, the differences in ATP 
Km for the different LRRK2 variants also indicate that relative kinase activity can be 
affected depending on the concentration of ATP used in the reactions, especially around 
or below the Km.   In the presence of Mg2+, the relative difference in kinase activity for 
G2019S versus WT LRRK2 is usually ~2 fold greater as reflected by the Vmax values.   
The molecular basis for the differences in catalytic rates between using Mg2+ versus Mn2+ 
are not clear and will require comprehensive structural analysis. However, it is possible 
that both metal cations may coordinate the placement and interactions of divalent cation-
ATP in the binding site differently, as such affecting the rate of the phosphoryl-transfer 
step. Alternatively, reduced rate of cation-ADP release, which can be a rate limiting step 
in protein kinase phosphorylation, may be the major property affected by Mn2+.  Indeed, 
Lovitt and colleagues have shown that LRRK2 displays a higher affinity for ADP in the 
presence of Mn2+ compared to Mg2+ (212). 
The dramatic alterations in the catalytic properties of LRRK2 in the presence Mn2+ 
caused by the G2019S mutation and the greater activity of this mutant is conceptually 
consistent with the role of this residue in the active site. G2019 is part of the highly 
conserved DFG motif in subdomain VII of the kinase domain (138, 168), and the D 
residue in this motif is involved in Mg2+ binding and proper coordination of Mg-ATP in 
the active site (67, 170, 200, 315).  The relative higher ATP Km, especially in the 
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presence of Mn2+, compared to WT LRRK2, suggests that a more rapid exchange of Mn-
ATP/ADP at the active site may be partially responsible for the increased catalytic rate of 
G2019S LRRK2 in the presence of Mn2+. The DFG motif is located at the N-terminal 
hinge region of the activation loop that switches from an open and extended 
conformation in the active state to a more closed conformation in the inactive state (67, 
168, 315), and this G residue is thought to play an important role in inducing proper 
orientation of the D residue (183).  After inactivation, the G residue usually performs an 
extreme twist, thereby facilitating this D residue to turn away from the catalytic site. The 
lack of a side chain is thought to allow the G residue to make this turn with little steric 
hindrance.  The G2019S mutation may disrupt the ability of this movement, and could 
keep the D residue positioned in the active site for longer activation periods that may also 
contribute to a greater catalytic rate. Nevertheless, comprehensive structural analyses will 
be required to better understand the molecular affects of the G2019S mutation. 
The I2020T mutation, which changes the first residue following the DFG-motif, did not 
have a dramatic affect on the kinase kinetic properties as did the G2019S mutation. 
Nevertheless, consistent with other studies (273) the I2020T mutation demonstrated 
significantly reduced ATP Km for ATP. 
Studies of the effects of Mg2+ on the observed LRRK2 kinase activity indicate that 
increasing the concentration of Mg2+ beyond what is needed to saturate total ATP results 
in further activation of LRRK2. Lovitt and colleagues recently reported comparable data 
using a truncated version of LRRK2 (LRRK2970-2527)(212). Such an effect has been 
observed for several other kinases and in some cases has been attributed to a second Mg2+ 
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binding site (282, 306). Increasing the concentration of Mg2+ or Mn2+ up to 0.5mM in the 
presence of 200µM ATP increases LRRK2 kinase activity, but that is likely 
predominantly due to increasing the effective concentration of the cation-ATP complex. 
The data from Mn2+/Mg2+ competition assays with G2019S LRRK2 also suggest that 
between 0.1-0.5mM, Mn2+ may also promote the kinase activity of LRRK2 
independently of increasing Mn-ATP concentration. In contrast to Mg2+, increasing the 
concentration of Mn2+ beyond 2mM had an inhibitory affect on LRRK2 kinase activity, 
and a similar inhibitory effect observed by Lovitt and colleagues was attributed to 
decreased catalytic turnover (212).  In our studies, all LRRK2 variants demonstrated 
similar relative decreases in activity with increasing Mn2+ beyond 2mM, although for 
G2019S LRRK2, kinase activity remained relatively high at all concentrations of  Mn2+ 
compared to WT and other mutants of LRRK2. 
These enzymatic kinetic properties of LRRK2 may be more than just interesting in vitro 
experiments and may reflect important characteristics of this enzyme that were designed 
for biological functionality. Manganese is an essential metal that is widely used in certain 
manufacturing industries. Environmental or occupational exposure to high manganese 
levels can cause neurotoxicity with the development of a form of parkinsonism known as 
manganism (77, 258). Mn2+ is required for many enzymes and its levels in tissue are 
usually stable, but it can accumulate in certain brain regions, including the basal ganglia, 
following elevated exposure (77, 258). The homeostatic level of free Mn2+ in cells is 
maintained by various transporters and by binding to various proteins (12, 77). It is 
widely believed that in vivo, Mg2+ is the major ATP cofactor involved in kinase reactions 
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because of its higher abundance compared to any other divalent metal cation.  However, 
given the much greater affinity of LRRK2 for Mn-ATP compared to Mg-ATP (~40 fold 
lower Km), and our studies of the effects of sub-stoichiometric concentration of Mn2+ on 
Mg2+-mediated LRRK2 kinase activity, it is possible that Mn2+ may act as a potent 
inhibitor of LRRK2 kinase activity in vivo. As seen here, in the presence of Mg2+, co-
incubation with 100 fold lower concentrations of Mn2+ cause a significant reduction in 
the kinase activity of WT LRRK2; however this effect does not apply to the G2019S 
mutant, where no activity is lost.  Therefore, we hypothesize that LRRK2 may act as a 
sensor for increased cytoplasmic Mn2+ levels, which results in decreased kinase activity 
that would modulate downstream counteractive measures. As a consequence of its 
alterations in kinetic properties, it is predicted that the G2019S mutant would remain 
largely active at physiologically elevated Mn2+ levels and therefore this putative signaling 
pathway should be compromised. Though it can be difficult to directly demonstrate 
altered changes in enzyme activity in vivo as a consequence of alterations in specific ion 
levels, some in vivo studies have shown that elevated Mn2+ levels can decrease the 
activity of some kinases (266).  Direct in vivo studies of the proposed model of the 
effects of Mn2+ on WT and G2019S LRRK2 kinase activity are complicated by the many 
conflicting studies of the effects of LRRK2 on signal transduction pathways and the lack 
of robust specific in vivo markers of LRRK2 activity(130),  but in vivo studies of Mn2+ 
affects on LRRK2 kinase activity are currently under investigation.  Nevertheless, the 
studies described here provide important insights into the kinetic properties of the kinase 
activity of LRRK2 and pathogenic mutants as affected by divalent metal cations. 
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CHAPTER FIVE 
 
SUMMARY AND FUTURE DIRECTIONS 
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The goal of this thesis work was to explore the pathological and biochemical properties 
of LRRK2.  I have identified and characterized the clinical as well as neuropathological 
features of patients with LRRK2 mutations (55, 56, 105).  I further examined the effect of 
these pathological mutations on the biochemical function of LRRK2 in-vitro to determine 
how their aberration may lead to disease (53, 54, 340).  I also assessed various factors 
that alter LRRK2 kinase activity to understand possible therapeutic intervention points, as 
well as models for LRRK2-mediated toxicity. 
Patients With LRRK2 Mutations Present with Classical and Nonclassical 
Pathology, Regardless of Mutation Location 
 
Despite the strong prevalence of LRRK2 mutations in monogenic forms of PD, only a 
handful of cases have come to autopsy.  In 2006, we identified and characterized three 
patients with LRRK2 mutation (105); however this search was limited in the exons that 
were scanned.  We expanded the search by including additional regions of the gene, and 
in doing so, identified two new patients with LRRK2 mutation from a cohort with 
extensive PD and DLB (56).   
One subject carried the R793M substitution and presented with typical clinical and 
pathological features of PD, while the second was found to have a novel L1165P 
substitution, which presented with a more atypical pathology.  This patient had an onset 
at middle age with a long duration (34 years) and concomitant dementia.  Pathologically 
this patient presented with an abundance of tau pathology in the hippocampal formation 
without SPs (consistent with tangle predominant senile dementia).   Of special interest in 
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these two patients, but not in our three other G2019S carriers, was the identification of 
occasional cytoplasmic TDP-43 inclusions in the temporal cortex. 
In addition to the commonality of alpha-synuclein pathology of LRRK2 cases, the 
presence of tau pathology in a significant number of patients is notable.  Tau pathology is 
normally associated with Alzheimer’s disease, however mutations in tau have been 
shown to cause nigral loss in frontotemporal dementia with Parkinsonism where TDP-43 
inclusions are present (39, 241).  Furthermore, although not generally considered a 
pathological component of sporadic forms of PD, a recent GWAS study found gene 
association for tau in sporadic PD (82).  Given that cases with LRRK2 mutation lead to 
disease, and these cases can present with alpha-synuclein and/or tau pathology, it may be 
possible that LRRK2 functions upstream of these proteins.  Although, complicating a 
strict notion that LRRK2 promotes disease through alpha-synculein or tau are cases of 
LRRK2 mutation with pure nigral loss in the absence of pathological inclusions (139).   
It is not clear why autosomal dominant mutations within LRRK2 present with such a 
diverse pathology.  LRRK2’s two enzymatically active domains, which are surrounded 
by a number of protein-protein and protein-membrane interacting regions, make LRRK2 
a prime candidate for its involvement with multiple partners and possible disease 
pathways.  As previously stated, LRRK2 has been implicated in synpatic endocytosis, 
vesicle sorting, and neurite outgrowth and branching.  However, the divergent 
pathologies of LRRK2 mutation cannot simply be ascribed to a model of one domain, 
one outcome because even patients carrying the same mutation can present with different 
pathology (105). 
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So the question starts to become, how does LRRK2 confer disease susceptibility?  While 
the pathology alone of cases is currently insufficient to answer this question, there are 
some clues when paired with their genetics.  Like alpha-synuclein, LRRK2 follows an 
autosomal dominant mode of inheritance.  However, unlike multiplications of alpha-
synuclein, there does not appear to be a dosage effect for LRRK2 mutation.  
Homozygotes have the same phenotype with no earlier onset compared to heterozygotes 
(158).  While this does not rule out a strict gain of function model, it does complicate the 
possible mechanisms that LRRK2 mutation may convey toxicity.  A toxic gain of 
function is still probable, as is a dominant negative effect.  Mutant LRRK2 may pull 
binding partners from other pathways, incur changes in substrate specificity and interact 
with novel targets, or it may alter the response to a signaling pathway that now leads to 
disease.  In order to investigate these possibilities, we began to look at the biochemical 
properties of these mutations in vitro. 
LRRK2 is an Active Kinase that can be Targeted for Possible Therapeutic 
Intervention 
 
We created a novel system to purify full-length LRRK2 with active in-vitro kinase 
activity (53).  Using this system, we assessed the specificity of wildtype and mutant 
LRRK2 and found that the G2019S mutation, the most common disease causing 
alteration, markedly increased kinase activity.  Given the high prevalence of this 
mutation, this highlighted overactive kinase activity as possible intervention point for its 
aberrant effects.  To this end, we conducted a screen for molecular inhibitors and 
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identified several compounds that share a basic indolocarbazole structure which act as 
potent inhibitors of LRRK2 kinase activity. 
Early on, it was shown that LRRK2 expression in cells can lead to neurotoxicity, 
contingent upon an active kinase domain (131, 296).  While the pathways leading to 
disease are still in question, this did establish that the kinase domain could be a critical 
target to understand as well as mitigate LRRK2-mediated toxicity.  Herein, we were the 
first laboratory to publish and characterize a class of compounds capable of inhibiting 
LRRK2 kinase activity.   
While this list of compounds capable of inhibiting LRRK2 kinase activity been expanded 
over the few years since we published our study, it wasn’t until late 2010 that their utility 
had been shown in vivo (194).  As previously discussed, G2019S transgenic mice do not 
show any obvious neuropathological phenotypes, even when expressed 8-16 fold above 
endogenous levels (209).  However, this model relied on a tetracycline responsive 
Calcium/calmodulin-dependent protein kinase II-alpha (CaMKII) promoter.  Dawson and 
colleagues recently showed that injection of an HSV amplicon-based G2019S LRRK2 
construct directly into the substantia nigra results in inflammation and neurodegeneration 
while the wildtype does not (194).  Using this model, they were able to show that twice 
daily injections of kinase inhibitors attenuated the loss of dopaminergic neurons and the 
reduction in density of dopaminergic fibers. 
This study provides nice validation to our initial identification of kinase inhibitors, 
however their usefulness as a therapeutic for LRRK2-mediated PD still remains in 
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question.  While the study does show that this pathogenic mutation can lead to 
degeneration within the substantia nigra, it cannot be ascertained if this model would 
cause toxicity regardless of where G2019S LRRK2 was expressed, and if this can truly 
be representative of pathways involved in pathological LRRK2-mediated PD.  Afterall, 
mutations outside the kinase domain that have not been shown to have concrete or 
substantial effects on kinase activity are linked to disease.  This highlights the need to 
study how the G2019S mutation may mechanistically lead to degeneration, and what 
pathways it may partake in.  This is why we began to explore the effects of outside 
factors that may augment kinase activity. 
The G2019S Mutation May Alter LRRK2 Function, in Addition to Overall 
Activity 
 
The effect(s) of LRRK2 pathogenic mutations in vivo remains largely elusive; however, 
we have shown that the G2019S pathogenic mutation increases kinase activity, and this 
effect has consistently been observed by several other laboratories.  As previously stated, 
carriers homozygous for the G2019S mutation carry no higher risk, earlier onset, or 
greater severity of disease compared to heterozygous carriers.  Therefore, increased 
kinase activity of the G2019S mutant alone in the absence of any outside factor is 
unlikely to account for the pathogenicity of this mutation.  We took a more careful 
analysis of LRRK2 kinase activity and found that this mutation, relative to the wildtype 
and other pathogenic mutation may act in a novel pathway leading to disease by 
disrupting LRRK2 sensitivity to manganese kinase inhibition (54).   
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Of various divalent metal cations, only Mg2+ or Mn2+ can support LRRK2 kinase activity.  
However, for wild-type, I2020T, and R1441C LRRK2, Mn2+ was significantly less 
effective at supporting kinase activity compared to Mg2+.  In sharp contrast, both Mn2+ 
and Mg2+ were effective at supporting the activity of G2019S LRRK2.  These divergent 
effects associated with divalent cation usage and the G2019S mutation were 
predominantly due to differences in catalytic rates.  However, LRRK2 was shown to have 
a much lower (~40 fold) ATP Km for Mn-ATP compared to Mg-ATP.  Consequently, 
sub-stoichiometric concentrations of Mn2+ can act to inhibit the kinase activity of wild-
type, but not G2019S LRRK2 in the presence of Mg2+.  This shows a possible point 
where divergent activity could lead directly to toxicity. 
Over 75 amino acid substitutions have been found in LRRK2 (60), and the kinase 
activating G2019S is the most common (141).  While it’s fairly accepted that this 
mutation increases activity and that an active kinase domain is required for neurotoxicity, 
no direct correlation of hyperphosphorylated substrates has been found in LRRK2-
mediated PD.  Paired with the absence of any overt neuropathological phenotype in 
mouse overexpressing wildtype and mutant forms of LRRK2 (10, 68, 209, 322), as well 
the previously mentioned similarity between human heterozygous and homozygous 
carriers, suggests that LRRK2 toxicity is not a simple gain of function model.  A loss of 
function is also unlikely, as the knockout mice develop normally with no overt phenotype 
or neuropathology.  Any model of LRRK2-mediated toxicity will have to take these 
factors into account. 
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Our findings for the G2019S LRRK2 mutation, which focus on the disability to regulate 
overall kinase activity, implicate a more subtle toxic gain of function.  Here, LRRK2 may 
act as a censor within the cell, which transduces information through decreased kinase 
activity to modulate downstream counteractive measures. As a consequence of its 
alterations in kinetic properties, it is predicted that the G2019S mutant would remain 
largely active when challenged, and therefore this putative signaling pathway would be 
compromised.   
Some LRRK2 mutations could also alter signaling pathways through a dominant negative 
effect.  Given the relatively low kinetic rates published on LRRK2 kinase activity (54, 
210, 212, 244, 257, 273), LRRK2 may normally associate with signaling partners through 
its kinase domain in a pseduosubstrate fashion.  If mutations confer decreased sensitivity 
of LRRK2 to cellular stressors, then LRRK2 may still associate with these substrates, 
again preventing their participation in downstream counteractive measures. 
Given this type of model, it would be interesting to see how the various existing LRRK2 
transgenic animals would respond to manganese as well as other cellular stressors.  Some 
in-vivo data already suggests that LRRK2 may contribute to a protective effect that is lost 
upon introduction of mutation.  In C. elegans, paraquat treatment results in 98% mortality 
at 14 days, however transgenic expression of hLRRK2 rescues this toxicity to only 15% 
death, while the G2019S mutant offers no protection(279).  Similar effects occur for 
rotenone where hLRRK2 mortality drops from 96% to 20%, while the G2019S in this 
model protects only at 55%.  Disruption of the dLRRK gene in Drosophila can also cause 
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enhanced sensitivity to oxidative stress by hydrogen peroxide (337), which is also true for 
pathological mutants (Y1383C and I1915T) of dLRRK transgenic flies (157). 
Future Directions for Studying LRRK2 in PD 
 
Complicating to setting an overall role for LRRK2 in disease is the diverse and 
conflicting biochemical and pathological findings not only in the current thesis work, but 
in the overall literature.  At the present stage of research, it has been difficult to attribute 
a direct mechanism of LRRK2 contribution to disease because of two key factors: (1) a 
true physiological substrate has not yet been identified for LRRK2, and (2) it is poorly 
understood how outside stressors, environmental toxins, and general upstream factors 
may affect LRRK2 activity. 
Within our study of LRRK2 specificity, we tested a variety of kinase substrate 
recognition motifs and found no activity for LRRK2 outside of the previously identified 
ERM phosphorylation consensus sequence.  Specificity has also been assessed using a 
positional scanning peptide library, however this has provided no physiological substrates 
for LRRK2(244).  And while a handful of putative substrates have been designated 
(alpha-synuclein, beta-tubulin, moesin, 4E-BP), the majority have been disproved, or 
remain largely unconfirmed.  Currently, there is an absence of physiologically relevant 
LRRK2 kinase substrates.  
To this end, future efforts should be directed at expanding the search for LRRK2 
substrates.  Novel substrate identification is difficult as phosphorylation traditionally 
occurs at low stoichiometry and on targets expressed at low levels.  High-throughput 
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screening in the form of peptide microarray libraries allow for the presentation of 
substrates at levels detectable by radiometric assay, however this does have two major 
drawbacks: (1) it relies on immobilized substrates that may not contain the primary or 
secondary structure necessary for kinase recognition, and (2) reactions rely on an in-vitro 
kinetic assay that may be missing key cofactors required for proper kinase activity.  
There are more intensive methods utilizing chemically tagged ATP analogs that require 
remodeling of the ATP binding pocket of the kinase of interest that overcome these 
drawbacks (217), however microarray screening has proven to be a valid and productive 
starting point for substrate identification.  
If, as we have proposed, LRRK2 does activate downstream effectors only in the presence 
of certain cofactors, then it will be crucial to test LRRK2 in the presence of these 
cofactors as they may augment activity in the above studies.  We have already 
demonstrated that manganese can increase affinity by approximately ~40 fold for ATP, 
so it will be interesting to see if the use of this divalent cation versus the traditional 
magnesium may be useful in identifying novel substrates.  
Dimerization also has an increased affect on kinase activity, and recently it has been 
shown that LRRK2 can form heterodimers with LRRK1 (61, 176).  Currently, no lab has 
investigated the effect these heterodimers have on kinase activity or specificity of 
LRRK1 or LRRK2.  Given their similar expression patterns and high degree of 
homology, it has already been hypothesized that LRRK1 activity may account for the 
lack of phenotype in LRRK2 knockout mice (25).  Not only may there be overlap in the 
pathways of LRRK1 and LRRK2, they may form heterodimers in vivo that have novel 
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activity compared to homodimers.  Characterizing the activity of these heterodimers may 
lead to the identification of novel targets and signaling pathways involved in LRRK2-
mediated PD. 
Besides looking downstream of LRRK2, it is also vital to look upstream to understand 
what factors and proteins may affect and interact with LRRK2. Manganese exposure 
preferentially causes neurodegeneration of the basal ganglia where LRRK2 is moderately 
expressed.  In mouse mesencephalic cultures, manganese exposure at sub-toxic 
concentrations results in decreased neurite outgrowth (302), similar to effects seen for 
some mutants of LRRK2.  Furthermore, like LRRK2, toxic concentrations of manganese 
exposure lead to apoptosis through caspase 3 activation (192, 349).  The upstream 
proteins that lead to manganese-induced apoptosis have not yet been established, 
however, another PD-related protein has been suggested to play a role in this pathway. 
(208)  Up-regulation of alpha-synuclein occurs at the mRNA and protein level prior to 
caspase 3 activation and cell death in SH-SY5Y cells treated with manganese.  In 
addition, alpha-synuclein overexpression potentiates manganese-induced apoptosis while 
reduced expression through iRNA has a slight but significant protective effect.  PARK9 
(ATP13A2) has also been linked to manganese as well as alpha-synuclein, where it is 
protective for their toxicity in various cellular models (115, 283).  Given the similar toxic 
effects of mutant LRRK2, manganese, and alpha-synuclein, it may be possible that these 
proteins share signaling partners to mediate toxicity.  Furthermore, it will be interesting 
to see if wildtype LRRK2 has a protective effect in cellular models similar, and whether 
it interacts with PARK9. 
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Currently, no direct identification of any kinase that may phosphorylate LRRK2 has been 
published.  The difficulty in tracking substrate phosphorylation within the cell centers 
upon the simple fact that all protein kinases utilize ATP, making direct substrate 
phosphorylation by a single kinase impossible to track.  However, there are methods to 
“trap” the kinase responsible by covalently crosslinking the substrate of interest to its 
upstream affecter (216).  This is accomplished by replacing the targeted T/S/Y residue in 
the substrate of interest with a cysteine.  This modified substrate can be covalently 
crosslinked to the upstream kinase in the presence of chemically modified 5‘-
fluorosulfonylbenzoyl adenosine (FSBA), a general covalent inhibitor of protein kinases.  
This may provide a valuable method to track the upstream effectors of LRRK2 
constitutively phosphorylated residues S910 and S935.  Recently these residues have 
been implicated in binding LRRK2’s interaction with 14-3-3, as well as the stabilization 
and dimerization of LRRK2, however the pathway that regulates this activity is unknown 
(81, 243). 
There are many other aspects of study one could undertake for this complex multi-
domain protein.  Utilizing the information provided in this thesis work should provide 
valuable insight and tools for this task.  Given that LRRK2 mutations result in 
pathological consequences similar to idiopathic PD, and those mutations in LRRK2 are 
the most common known cause of familial and sporadic PD, understanding its 
physiological function may provide valuable insights into the development, etiology, and 
hopefully treatment of PD. 
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